

PATIENT INFORMATION

NAME: 844017048 ACC #: 844017048 DOB: 1/1/1900 SEX:

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: **RECEIVED DATE:** REPORT DATE: 6/24/2019

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Complete Panel

Risk Management

Type III Hyperlipoproteinemia

Unknown Association with Type III Hyperlipoproteinemia

The patient's results for the APOE c.388 T>C (Cys130Arg) mutation and/or APOE c.526 C>T (Arg176Cys) mutations are indeterminate.

The patient's risk for type III hyperlipoproteinemia cannot be estimated accurately.

Consult with a genetic counselor for more information.

Hyperhomocysteinemia - Depression

No Increased Risk of Hyperhomocysteinemia

The patient does not carry the MTHFR C677T variant. MTHFR enzyme activity is normal.

Patients diagnosed with depression often have low folate levels and homocysteine is a highly sensitive marker of folate status. Functional folate deficiency is indicated by elevated homocysteine. With a normal MTHFR activity, this patient can process folate normally and is unlikely to have elevated plasma levels of homocysteine.

Patients diagnosed with depression: as lower folate levels are associated with poorer antidepressant response, and baseline levels of folate within the normal range predict antidepressant response, testing for homocysteine levels and serum folate levels may be informative for this patient before prescribing methylfolate as an antidepressant-augmenting agent.

Thrombophilia

No Increased Risk of Thrombosis

The patient does not carry the Factor V Leiden G1691A mutation or Factor II G20210A mutation (wild-type).

The patient's risk of thrombosis is not increased (average risk of clotting is about 1 in 1000 for anyone in a year). However, because this test cannot find all of the inherited reasons for abnormal clotting, other factors may affect this risk assessment.

Unless other genetic and/or circumstantial risk factors are present (e.g., smoking or obesity...), estrogen-containing contraceptive and hormone replacement therapy can be used by the patient.

Hyperhomocysteinemia - Thrombosis

No Increased Risk of Hyperhomocysteinemia

The patient does not carry the MTHFR C677T or MTHFR A1298C mutation (wild-type). MTHFR enzyme activity is normal.

With a normal MTHFR activity, this patient is unlikely to have elevated plasma levels of homocysteine, which is a known risk factor for cardiovascular diseases and thrombosis. Unless other risk factors are present, the patient is not expected to have an increased risk for venous thromboembolism (VTE).

MTHFR enzyme activity is normal.

\times	A medication has potentially reduced efficacy, increased toxicity or the patient has an increased risk for the indicated condition. Guidelines exist for adjusting dosage, increased vigilance or the patient has a moderate risk for the indicated condition.	ACTIONABLE	Recommendations based upon publications by international pharmacogenetic expert groups, consortia or regulatory bodies (CPIC, DPWG, FDA. EMA). Recommendations are suitable for implementation in a clinical setting. Guidelines may change as knowledge arises.
\checkmark	The medication can be prescribed according to standard regimens or the patient's risk for the indicated condition is not increased.	INFORMATIVE	There are insufficient or contradictory findings documenting the impact of a given genetic polymorphism or drug interaction. Recommendations are informative and implementation in a clinical setting is optional.





PATIENT INFORMATION

SPECIMEN DETAILS

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Potentially Impacted Medications

CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
Anticancer Agents	Antifolates	Methotrexate (Trexall)		
	Angiotensin II Receptor Antagonists	Azilsartan (Edarbi, Edarbyclor) Candesartan (Atacand) Eprosartan (Teveten) Irbesartan (Avapro) Losartan (Cozaar, Hyzaar) Olmesartan (Benicar) Telmisartan (Micardis) Valsartan (Diovan, Entresto)		
	Antianginal Agents	Ranolazine (Ranexa)		
	Antiarrhythmics	Flecainide (Tambocor) Mexiletine (Mexitil) Propafenone (Rythmol)		
	Anticoagulants	Apixaban (Eliquis) Betrixaban (Bevyxxa) Dabigatran Etexilate (Pradaxa) Edoxaban (Savaysa) Fondaparinux (Arixtra) Rivaroxaban (Xarelto)	Warfarin (Coumadin)	
Cardiovascular	Antiplatelets	Prasugrel (Effient) Ticagrelor (Brilinta) Vorapaxar (Zontivity)	Clopidogrel (Plavix)	
	Beta Blockers	Atenolol (Tenormin) Bisoprolol (Zebeta) Carvedilol (Coreg) Labetalol (Normodyne, Trandate) Metoprolol (Lopressor) Nebivolol (Bystolic) Propranolol (Inderal) Timolol (Timoptic)		
	Diuretics	Torsemide (Demadex)		
	Statins	Fluvastatin (Lescol)	Atorvastatin (Lipitor) Lovastatin (Mevacor, Altoprev, Advicor) Pitavastatin (Livalo) Pravastatin (Pravachol) Rosuvastatin (Crestor)	Simvastatin (Zocor)
	Meglitinides	Nateglinide (Starlix) Repaglinide (Prandin, Prandimet)		
Diabetes	Sulfonylureas	Chlorpropamide (Diabenese) Glimepiride (Amaryl) Glipizide (Glucotrol) Glyburide (Micronase) Tolbutamide (Orinase)		



	anchest	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
V Ur	RPOSES ONLY - NOT FOR CLINICAL L	ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018	
CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
Gastrointestinal	Antiemetics	Aprepitant (Emend-oral) Dolasetron (Anzemet) Dronabinol (Marinol) Fosaprepitant (Emend-i.v) Granisetron (Sancuso, Sustol) Metoclopramide (Reglan) Netupitant-Palonosetron (Akynzeo) Ondansetron (Zofran, Zuplenz) Palonosetron (Aloxi) Rolapitant (Varubi)		
	Proton Pump Inhibitors	Rabeprazole (Aciphex)	Dexlansoprazole (Dexilant, Kapidex) Esomeprazole (Nexium) Lansoprazole (Prevacid) Omeprazole (Prilosec) Pantoprazole (Protonix)	
Infections	Antifungals	Amphotericin B (AmBisome, Abelcet) Anidulafungin (Eraxis) Caspofungin (Cancidas) Fluconazole (Diflucan) Isavuconazonium (Cresemba) Itraconazole (Sporanox) Micafungin (Mycamine) Posaconazole (Noxafil)		Voriconazole (Vfend)
	Anti-HIV Agents	Dolutegravir (Tivicay, Triumeq) Raltegravir (Isentress, Dutrebis)		
	Antimalarials	Proguanil (Malarone)		





SPECIMEN DETAILS

1/1/1900

2/8/2018

ORDERED BY

SPECIMEN TYPE: **COLLECTION DATE:** 1/1/1900 RECEIVED DATE: REPORT DATE:

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
	Fibromyalgia Agents	Milnacipran (Savella)		
	Muscle Relaxants	Cyclobenzaprine (Flexeril, Amrix) Metaxalone (Skelaxin) Methocarbamol (Robaxin)	Carisoprodol (Soma) Tizanidine (Zanaflex)	
Pain	NSAIDs	Celecoxib (Celebrex) Diclofenac (Voltaren) Flurbiprofen (Ansaid) Ibuprofen (Advil, Motrin) Indomethacin (Indocin) Ketoprofen (Orudis) Ketorolac (Toradol) Meloxicam (Mobic) Nabumetone (Relafen) Naproxen (Aleve) Piroxicam (Feldene) Sulindac (Clinoril)		
	Opioids	Alfentanil (Alfenta) Buprenorphine (Butrans, Buprenex) Codeine (Codeine; Fioricet with Codeine) Dihydrocodeine (Synalgos-DC) Hydromorphone (Dilaudid, Exalgo) Levorphanol (Levo Dromoran) Meperidine (Demerol) Methadone (Dolophine) Oxycodone (Percocet, Oxycontin) Oxymorphone (Opana, Numorphan) Sufentanil (Sufenta) Tapentadol (Nucynta) Tramadol (Ultram)	Fentanyl (Actiq) Hydrocodone (Vicodin) Morphine (MS Contin)	
	Antiaddictives	Bupropion (Wellbutrin, Zyban, Aplenzin, Contrave) Naltrexone (Vivitrol, Contrave)		
	Anti-ADHD Agents	Amphetamine (Adderall, Evekeo) Atomoxetine (Strattera) Clonidine (Kapvay) Dexmethylphenidate (Focalin) Dextroamphetamine (Dexedrine) Guanfacine (Intuniv) Lisdexamfetamine (Vyvanse) Methylphenidate (Ritalin, Aptensio XR, Concerta, Metadate ER, Quillivant ER)		



	anchest		SPECIMEN DETAILS	ORDERED BY
		NAME: Patient 35962	SPECIMEN TYPE:	
	Iversity	ACC #: 35962 DOB: 1/1/1900	COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900	
FOR ACADEMIC PURP	OSES ONLY - NOT FOR CLINICAL	SEX: USE	REPORT DATE: 2/8/2018	
CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES

	Anticonvulsants	Brivaracetam (Briviact) Carbamazepine (Tegretol, Carbatrol, Epitol) Eslicarbazepine (Aptiom) Ethosuximide (Zarontin) Ezogabine (Potiga) Felbamate (Felbatol) Fosphenytoin (Cerebyx) Gabapentin (Neurontin) Lacosamide (Vimpat) Lamotrigine (Lamictal) Levetiracetam (Keppra) Oxcarbazepine (Trileptal, Oxtellar XR) Perampanel (Fycompa) Phenobarbital (Luminal) Phenytoin (Dilantin) Pregabalin (Lyrica) Primidone (Mysoline) Rufinamide (Banzel) Tiagabine (Gabitril) Topiramate (Topamax) Valproic Acid (Depakote, Depakene) Vigabatrin (Sabril) Zonisamide (Zonegran)		
	Antidementia Agents	Donepezil (Aricept) Galantamine (Razadyne) Memantine (Namenda)		
Psychotropic	Antidepressants	Amoxapine (Amoxapine) Desipramine (Norpramin) Desvenlafaxine (Pristiq) Duloxetine (Cymbalta) Fluoxetine (Prozac, Sarafem) Fluvoxamine (Luvox) Levomilnacipran (Fetzima) Maprotiline (Ludiomil) Mirtazapine (Remeron) Nefazodone (Serzone) Nortriptyline (Pamelor) Paroxetine (Paxil, Brisdelle) Protriptyline (Vivactil) Trazodone (Oleptro) Venlafaxine (Effexor) Vilazodone (Viibryd) Vortioxetine (Trintellix)	Sertraline (Zoloft)	Amitriptyline (Elavil) Citalopram (Celexa) Clomipramine (Anafranil) Doxepin (Silenor) Escitalopram (Lexapro) Imipramine (Tofranil) Trimipramine (Surmontil)



FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE		NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN DETAILSSPECIMEN TYPE: COLLECTION DATE:1/1/1900RECEIVED DATE:1/1/1900REPORT DATE:2/8/2018	ORDERED BY
		STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
		Aripiprazole (Abilify, Aristada) Asenapine (Saphris) Brexpiprazole (Rexulti)		
		Cariprazine (Vraylar) Chlorpromazine (Thorazine)		

Clozapine (Clozaril)

Olanzapine (Zyprexa)

Diazepam (Valium)

Tetrabenazine (Xenazine)

Fluphenazine (Prolixin) Haloperidol (Haldol) Iloperidone (Fanapt) Loxapine (Loxitane, Adasuve) Lurasidone (Latuda)

Paliperidone (Invega)

Perphenazine (Trilafon) Pimavanserin (Nuplazid) Pimozide (Orap) Quetiapine (Seroquel) Risperidone (Risperdal) Thioridazine (Mellaril) Thiothixene (Navane) Trifluoperazine (Stelazine) Ziprasidone (Geodon) Alprazolam (Xanax)

Clobazam (Onfi)

Clonazepam (Klonopin) Deutetrabenazine (Austedo) Dextromethorphan / Quinidine

(Nuedexta)

Flibanserin (Addyi) Valbenazine (Ingrezza) Colchicine (Mitigare)

Febuxostat (Uloric)

Lesinurad (Zurampic)

Apremilast (Otezla)

Leflunomide (Arava) Tofacitinib (Xeljanz)

Tacrolimus (Prograf)

Antipsychotics

Benzodiazepines

Other Neurological

Agents

Anti-Hyperuricemics

and Anti-Gout Agents

Immunomodulators

Immunosuppressants

	Powered By
5	Translational
	software

Rheumatology

Transplantation

$\langle \nabla \rangle \mathbf{M}$	anchoct		SPECIMEN DETAILS	ORDERED BY
	anchest iversity	SEX:	SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018	
CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
	5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia	Dutasteride (Avodart) Finasteride (Proscar)		
	Alpha-Blockers for Benign Prostatic Hyperplasia	Alfuzosin (UroXatral) Doxazosin (Cardura) Silodosin (Rapaflo) Tamsulosin (Flomax) Terazosin (Hytrin)		
Urologicals	Antispasmodics for Overactive Bladder	Darifenacin (Enablex) Fesoterodine (Toviaz) Mirabegron (Myrbetriq) Oxybutynin (Ditropan) Solifenacin (Vesicare) Tolterodine (Detrol) Trospium (Sanctura)		
	Phosphodiesterase Inhibitors for Erectile Dysfunction	Avanafil (Stendra) Sildenafil (Viagra) Tadalafil (Cialis)		

Vardenafil (Levitra)



Dysfunction



FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Dosing Guidance

PATIENT INFORMATION

NAME: Patient 35962

ACC #: 35962

SEX:

DOB: 1/1/1900

SPECIMEN DETAILS

COLLECTION DATE: 1/1/1900

1/1/1900

2/8/2018

SPECIMEN TYPE:

RECEIVED DATE:

REPORT DATE:

ORDERED BY

\otimes	Amitriptyline	Increased Sensitivity to Amitriptyline (CYP2C19: Rapid Metabolizer)	INFORMATIVE
	Elavil	Consider an alternative drug, or consider prescribing amitriptyline at standard dose and monitor concentrations of amitriptyline and nortriptyline to guide dose adjustments.	the plasma
\otimes	Citalopram	Insufficient Response to Citalopram (CYP2C19: Rapid Metabolizer)	ACTIONABLE
	Celexa	At standard label-recommended dosage, citalopram plasma concentrations levels are expected t result in a loss of efficacy. Consider an alternative medication. If citalopram is warranted, conside maximum of 150% and titrate based on the clinical response and tolerability.	
\otimes	Clomipramine	Increased Sensitivity to Clomipramine (CYP2C19: Rapid Metabolizer)	INFORMATIVE
	Anafranil	Consider an alternative drug, or consider prescribing clomipramine at standard dose and monito concentrations of clomipramine and desmethyl-clomipramine to guide dose adjustments.	or the plasma
\otimes	Doxepin	Increased Sensitivity to Doxepin (CYP2C19: Rapid Metabolizer)	INFORMATIV
	Silenor	Consider an alternative drug, or consider prescribing doxepin at standard dose and monitor the doxepin and desmethyl-doxepin to guide dose adjustments.	plasma concentrations of
\otimes	Escitalopram	Insufficient Reponse to Escitalopram (CYP2C19: Rapid Metabolizer)	ACTIONABL
	Lexapro	At standard label-recommended dosage, escitalopram plasma concentrations levels are expected result in a loss of efficacy. Consider an alternative medication. If escitalopram is warranted, consist to a maximum of 150% and titrate based on the clinical response and tolerability.	
\otimes	Imipramine	Increased Sensitivity to Imipramine (CYP2C19: Rapid Metabolizer)	INFORMATIV
	Tofranil	Consider an alternative drug, or consider prescribing imipramine at the standard dose and monit concentrations of imipramine and desipramine to guide dose adjustments.	tor the plasma
\otimes	Simvastatin	Intermediate Myopathy Risk (SLCO1B1: Decreased Function)	ACTIONABL
	Zocor	Simvastatin plasma concentrations are expected to be elevated. Consider avoiding simvastatin alternative statin or another hypolipidemic drug, or consider prescribing simvastatin at a lower s Routine creatine kinase (CK) monitoring is also advised. The FDA recommends against the 80 the association between the SLCO1B1 521C>T variant and myopathy risk is not clearly establisher as atorvastatin, pitavastatin, rosuvastatin, and pravastatin, caution is advised if high doses of the patient. Fluvastatin plasma levels are not affected by the SLCO1B1 521C>T variant.	tarting dose (20 mg/day) mg daily dose. Although d for other statins such
\otimes	Trimipramine	Increased Sensitivity to Trimipramine (CYP2C19: Rapid Metabolizer)	INFORMATIVI
	Surmontil	Consider an alternative drug, or consider prescribing trimipramine at standard dose and monitor concentrations of trimipramine and desmethyl-trimipramine to guide dose adjustments.	r the plasma
\otimes	Voriconazole	Non-Response to Voriconazole (CYP2C19: Rapid Metabolizer)	ACTIONABL
_	Vfend	Voriconazole plasma concentrations are expected to be low if a standard dose is used, increasing response and effectiveness and subsequent disease progression. Consider an alternative medicate dependent on CYP2C19 metabolism, such as isavuconazole, liposomal amphotericin B or posaco	tion that is not




	A Manch	nester	PATIENT INFORMATION NAME: Patient 35962	SPECIMEN DETAILS	ORDERED BY		
	Univer		ACC #: 35962 DOB: 1/1/1900 SEX:	Specimen Type: COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018			
、 '	FOR ACADEMIC PURPOSES ONLY - NO						
	Atorvastatin <i>Lipitor</i>	The reduced SLCO1 in patients with high atorvastatin is used myopathy predispo	n statin plasma levels, the use o in this patient, a closer monitor	ted atorvastatin plasma levels. Bec f high atorvastatin doses in this pa	liver function is recommended. Oth		
N	Carisoprodol	Altered Sensitivit	y to Carisoprodol (CYP2C19	9: Rapid Metabolizer)	INFORMATI		
	Soma		data to allow calculation of dos carefully monitor the patient for		rescribed, it is recommended to use		
	Clopidogrel	Increased Respor	nse to Clopidogrel (CYP2C1	9: Rapid Metabolizer)	ACTIONAB		
	Plavix		prescribed at standard label-re- eding while taking clopidogrel.	commended dosage. Individuals w	vith the *17 allele may have an		
	Clozapine	Possible Sensitivity/Non Response to Clozapine (CYP1A2: Intermediate Metabolizer - INFORMATIVE Possible Inducibility)					
	Clozaril	The patient may hav and careful titration drug levels, leading	ve high plasma drug levels at us are recommended until a favo	sual doses, which may lead to mor rable response is achieved. Smokin nerapeutic drug monitoring accon	ng cessation may increase plasma		
	Dexlansoprazole	Insufficient Respo	onse to Dexlansoprazole (C	YP2C19: Rapid Metabolizer)	INFORMATI		
	Dexilant, Kapidex			ose by 200% and be alert to insuff se and consider dose increase of 2			
	Diazepam Valium	CYP2C19 rapid and metabolizers. Howe	ver, there is insufficient data to	olize diazepam and nordiazepam allow calculation of dose adjustm			
2	F		's response and adjust the dose				
<u>.</u>	Esomeprazole Nexium	Helicobacte	1.5	ose by 50-100% and be alert to in: se and consider dose increase of 5	•		
	Fentanyl	Altered Response	e to Fentanyl (OPRM1: Alter	ed OPRM1 Function)	INFORMATI		
	Actiq	genotype has been require higher dose	shown to be associated with re s of this drug. Because fentanyl	÷	Ind cancer pain: the patient's Inyl doses. Therefore, the patient m , it is advised to carefully titrate this		
	Hydrocodone	-	e to Hydrocodone (OPRM1:		INFORMATI		
	Vicodin	genotype has been	shown to be associated with re	G mutation. Acute postoperative a duced analgesia and increased op to increased hydrocodone doses, a	ioid side effects at standard or high		

V	Univer	hester csity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:		1/1/1900 1/1/1900 2/8/2018	
F	FOR ACADEMIC PURPOSES ONLY - N	IOT FOR CLINICAL USE				
<u>^</u>	Lansoprazole Prevacid	Helicobacte	onse to Lansoprazole (CYP2 er pylori eradication: increase de xtra alert to insufficient respons	ose by 200% and be alert t	to insufficient response.	INFORMATIV
<u>^</u>	Lovastatin Mevacor, Altoprev, Advicor	The reduced SLCO1 increases in patients lovastatin is used in	thy Risk (SLCO1B1: Decreas B1 function may result in elevat s with high statin plasma levels, this patient, a closer monitorin sing factors include advanced a female gender.	ed lovastatin acid plasma the use of high lovastatin g of serum creatine kinase	doses in this patient shoul and liver function is recon	d be avoided. If nmended. Other
<u>^</u>	Morphine MS Contin	The patient carries of genotype has been risk for nausea and	e to Morphine (OPRM1: Alte one copy of the OPRM1 118A> shown to be associated with po vomiting during the first 24-ho The dosing regimen needs to be experience.	6 mutation. Acute postope ssible reduced analgesia ur postoperative period. T	at standard morphine dose herefore, the patient may r	s and decreased equire higher
<u>^</u>	Morphine MS Contin	Altered Response to Morphine (COMT: High/Normal COMT Activity) INFORM The patient does not carry the COMT Val158Met mutation. The patient may require higher doses of morphine for adequate pain control. The dosing regimen needs to be individualized for each patient, taking into account the pati prior analgesic treatment experience.				
	Olanzapine Zyprexa	Possible Inducibi There is little eviden for non-response at may increase plasm	ty/Non Response to Olanza lity) ace regarding the impact of CYF standard doses. Careful monit a drug levels, leading to advers be needed in patients who have	1A2 genetic variants on o pring is recommended due e events. Therefore, therag	lanzapine response. Smoke ring dosing adjustment. Sm	noking cessation
<u>^</u>	Omeprazole Prilosec	Helicobacte	onse to Omeprazole (CYP2) er pylori eradication: increase de xtra alert to insufficient respons	ose by 100-200% and be a	alert to insufficient response	ACTIONABL e.
<u>^</u>	Pantoprazole Protonix	Helicobacte	onse to Pantoprazole (CYP2 er pylori eradication: increase de xtra alert to insufficient respons	ose by 400% and be alert t	to insufficient response.	ACTIONABL
	Pitavastatin Livalo	The reduced SLCO1 in patients with high pitavastatin is used	thy Risk (SLCO1B1: Decreas B1 function may result in elevat n statin plasma levels, the use o in this patient, a closer monitor sing factors include advanced a female gender.	ed pitavastatin plasma lev f high pitavastatin doses in ing of serum creatine kina	n this patient should be ave ase and liver function is reco	oided. If ommended. Other

	Mancl Univer	hester sitv	PATIENT INFORMATION NAME: Patient 35962 ACC #: 35962	SPECIMEN DETAILS SPECIMEN TYPE: COLLECTION DATE: 1/1/1900	ORDERED BY
	· · · · · · · · ·		DOB: 1/1/1900 SEX:	RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018	
I	FOR ACADEMIC PURPOSES ONLY - NO	OT FOR CLINICAL USE			
	Pravastatin Pravachol	The reduced SLCO1 in patients with high pravastatin is used i	n statin plasma levels, the use of n this patient, a closer monitori sing factors include advanced a	ed Function) ed pravastatin plasma levels. Becau: f high pravastatin doses in this patie ng of serum creatine kinase and live ge (≥65), uncontrolled hypothyroidi	ent should be avoided. If r function is recommended. Other
	Rosuvastatin	Increased Myopa	thy Risk (SLCO1B1 521T>C 1	[/C)	INFORMATIVE
	Crestor	in patients with high rosuvastatin is used	n statin plasma levels, the use of in this patient, a closer monitor sing factors include advanced a	ed rosuvastatin plasma levels. Becau f high rosuvastatin doses in this pati ing of serum creatine kinase and liv ge (≥65), uncontrolled hypothyroidi	ient should be avoided. If er function is recommended. Othe
	Sertraline	Possible Reduced	Response to Sertraline (CY	/P2C19: Rapid Metabolizer)	INFORMATIV
	Zoloft	-	escribed at standard label-recor Itenance dosing, consider an alt	nmended dosage and administratic ernative medication.	n. If patient does not respond to
	Tetrabenazine	Normal Sensitivit	y to Tetrabenazine (CYP2D	6: Normal Metabolizer)	ACTIONABL
	Xenazine	required. The first w weekly intervals by with a maximum s	eek's starting dose is 12.5 mg d 12.5 mg to a tolerated dose. Th ingle dose of 37.5 mg . If seriou	s disease: Individualization of dose laily; second week, 25 mg (12.5 mg f e maximum daily dose in CYP2D6 us adverse events occur, titration sh ent(s) do not resolve, consider withd	twice daily); then slowly titrate at 5 normal metabolizers is 100 mg, ould be stopped and the dose of
Â	Tizanidine Zanaflex	Possible Inducibi There is little eviden	ity) ace regarding the impact of CYP	dine (CYP1A2: Intermediate Me 1A2 genetic variants on tizanidine r ere is an association between high	esponse. Smokers may be at risk
		and the risk of hypo adjustment. Smokin	tension and excessive sedation. g cessation may increase plasm	Therefore, careful monitoring is rec a drug levels, leading to excessive h e needed in patients who have quit	commended during dosing hypotension and sedation. Careful
	Warfarin	Moderate Sensiti	vity to Warfarin (CYP2C9 *1	/*1 VKORC1 -1639G>A A/A)	ACTIONABL
	Coumadin	FDA-approved labe	, i	 Consider using the following warf ng a personalized dose calculated b s. 	U
	Alfentanil	Normal Response	e to Alfentanil		INFORMATIVE
	Alfenta	showed that CYP3A	5 genotype had no effect on the macy guidance: Alfentanil sho	metabolized by CYP3A4 and CYP3A e systemic or apparent oral clearanc uld be used with caution when pres	es, or pharmacodynamics of
\checkmark	Alfuzosin	Normal Response	e to Alfuzosin		INFORMATIV
-	UroXatral	Polypharmacy guid Alfuzosin is contrai	dance: Alfuzosin is extensively r ndicated with strong CYP3A4 r concentrations. Take caution	d drug selection or dosing recomm netabolized by CYP3A4 into pharma inhibitors, as the risk for QTc pro when this drug is prescribed with C	acologically inactive metabolites. longation induced by this drug is
	owered By		Genetic Test Results For Patie		

	Manch	lector	PATIE	NT INFORMATION	SPECIMEN DETAILS		ORDERED BY
	Univer	sity		Patient 35962 35962 1/1/1900	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018	
F	FOR ACADEMIC PURPOSES ONLY - NOT	FOR CLINICAL USE					
	Alprazolam Xanax	polymorphisms of th guidance: The conc prolonged sedation. exaggerated sedativ	nuidance nese gen omitant Impairm e effects e, itraco	e: Alprazolam is primar es are not expected to use of alprazolam with nent of motor skills are . If possible, alprazolan nazole and ritonavir. Do	affect the efficacy or saf CYP3A4 inhibitors may also observed with som should be avoided in p	ety profiles of result in incre e combination patients receiv	INFORMATIN A4 and CYP3A5. Genetic this drug. Polypharmacy ased alprazolam levels and as. Monitor patients for ng strong inhibitors of CYP3A4 decrease alprazolam levels,
1	Amoxapine Amoxapine			-	Normal Metabolizer)	administratio	INFORMATIV
/	Amphetamine	Normal Exposure	to Am	ohetamine (CYP2D6	: Normal Metabolizer	r)	INFORMATI
	Adderall, Evekeo	Amphetamine can b	e prescri		ecommended dosage a		tion. Individualize the dosage
/	Amphetamine	Good Response to	o Ampł	netamine salts (CON	IT: High/Normal CON	/IT Activity)	INFORMATI
	Adderall, Evekeo		-		ihood of response to an osage should be individ	-	imulants. Amphetamines should
	Amphotericin B AmBisome, Abelcet	of a given dose bein genetically guided d medications such as induced renal toxicit	g excret rug sele aminog y, and sł	Amphotericin B is exi ed in the biologically a ction or dosing recomr lycosides, cyclosporine nould be used concom	ctive form. Details of pos nendations are available and pentamidine may e	ssible metabo • Polypharma enhance the p oution. Intensiv	ACTIONABI ths) by the kidneys with 2 to 59 lic pathways are unknown. No acy guidance: Nephrotoxic otential for amphotericin B- ve monitoring of renal function
/	Anidulafungin	Normal Response	to Ani	dulafungin			ACTIONAB
	Eraxis	Pharmacogenetic g activity and which is has not been observ	j uidance subsequ ed. Anid	e: Anidulafungin under iently converted to pep ulafungin is not a subs		minated. Hep or of cytochro	peptide that lacks antifungal atic metabolism of anidulafung me P450 enzymes. No
/	Apixaban	Normal Response	to Api	xaban			INFORMATI
	Eliquis	Pharmacogenetic g primarily by CYP3A4 efflux transport prot genetic variations ar dosing adjustments administered with ke increase). Hence, for is coadministered wi ritonavir, and clarith	and CYI eins P-g e unlikel are reco toconaz patients th drugs romycin) and P-g	e: Apixaban is not exter P3A5, with minor contr p (ABCB1) and BCRP (A y to have a clinically sig mmended. Polypharm cole, a strong CYP3A/P- s receiving 5 mg twice that are strong dual ir l. In patients already ta gp should be avoided.	butions from CYP1A2 ar BCG2). While these enzy gnificant impact on apixa acy guidance: Exposura gp inhibitor. This transla daily, apixaban dose sho shibitors of CYP3A4 and king 2.5 mg twice daily, o No dose adjustment is re	nd CYP2J2. Th mes and tran aban exposure e to apixaban ates into an in uld be decrea P-gp (e.g., kei coadministrati ecommended	the dose is metabolized is drug is a substrate for the sporters are polymorphic, e, and no genotype-based increases by 100% when co- creased bleeding risk (70% sed to 2.5 mg twice daily when coconazole, itraconazole, on of apixaban with strong dua when co-administered with



	Manal	lactor	PATIENT	INFORMATION	SPECIMEN DETAILS		ORDERED BY
V	Manch Univer	sity	ACC #: 3	atient 35962 5962 /1/1900	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018	
	FOR ACADEMIC PURPOSES ONLY - NO	T FOR CLINICAL USE					
	Asenapine	Normal Respons					INFORMATIVI
	Saphris	metabolism route of demethylation path CYP2D6. There are asenapine disposit Asenapine should guidance: Coadmi as asenapine plasm activity, has a limite coadministration w	occurs via dii nway as well no studies d on and there oe prescriber nistration of na concentra ed effect on ith paroxetir strong enzy	ect glucuronidation as the oxidative read ocumenting the effe e are no available ge d based on the clinic asenapine with CYP tions will increase re asenapine plasma co he (both a substrate me inducers (e.g. car	catalyzed by UGT1A4. A tions catalyzed by CYP1 ct of genetic polymorph netically guided drug se al response and tolerab IA2 inhibitors such as fl sulting in more side effe ncentrations. Asenapine and an inhibitor of CYP2	Also important A2 with contri- nisms of these election or dos ility of the indi uvoxamine sho ects. Cigarette e is a weak inh 2D6) should be	tive metabolites. The primary but less pronounced is the butions from CYP3A4 and metabolizing enzymes on ing recommendations. vidual patient. Polypharmacy buld be approached with caution smoking, which induces CYP1A2 bitor of CYP2D6 and its approached with caution. Long y decrease asenapine exposure
	Atenolol	Normal Respons	e to Ateno	lol			INFORMATIVI
V	Tenormin	Normal Response to Atenolol Pharmacogenetic guidance: The bioavailability of atenolol is approximately 40–50% and renal excretion approximately 90% of the absorbed drug in its unchanged form. A negligible amount of the drug is met Atenolol is a substrate of several organic anion and cation transporters including SLC22A1, SLC22A2, SLC SLC47A2. No genetically-guided drug selection or dosing recommendations are available.					
	Atomoxetine	Normal Sensitivi	ty to Atom	oxetine (CYP2D6:	Normal Metabolizer	<i>.</i>)	ACTIONABL
	Strattera	recommended unt	il a favorable	response is achieve	commended dosage an d. The maximum recom ients with a body weigh	mended daily	dose is 1.4 mg/kg for patients
	Avanafil	Normal Respons	e to Avana	fil			INFORMATIV
-	Stendra	Polypharmacy gu strong CYP3A4 in indinavir, itraconaz as erythromycin, ar	i dance: Avai hibitors suc ole, nefazod nprenavir, aj	hafil is extensively mo h as ketoconazole, it one, nelfinavir, saqui prepitant, diltiazem,	aconazole, voriconazole navir, and telithromycin	herefore Avar e, ritonavir, ata . If taking a mo avir, or verapar	afil should not be used with zanavir, clarithromycin, oderate CYP3A4 inhibitor, such nil, the dose should be no more
	Azilsartan	Normal Sensitivi	ty to Azilsa	artan Medoxomil	CYP2C9: Normal Me	tabolizer)	INFORMATIV
	Edarbi, Edarbyclor	Azilsartan medoxo	mil is hydrol	/zed to azilsartan, its	active metabolite, in th	e gastrointesti	nal tract during absorption. pel-recommended dosage and
	Betrixaban	Normal Respons	e to Betrix	aban			ACTIONABL
_	Веvухха	cytochrome P450 e CYP2C9, CYP2C19, urinary excretion. E polymorphic, gene genotype-based de	enzymes-bas CYP2D6 and etrixaban is tic variations osing adjustr	ed metabolism (less CYP3A4). The main a substrate for the e are unlikely to have nents are available.	elimination pathway of flux transport protein P a clinically significant ir Polypharmacy guidanc	netabolized by the drugs is bi -gp (ABCB1) a npact on betriz : e: Concomitat	e hydrolysis with minor CYP1A1, CYP1A2, CYP2B6, liary excretion followed by nd while this transporter is kaban exposure, and no nt use with P-gp inhibitors such plasma levels of betrixaban and

	7 Manal	hostor	PATIENT INFORMATION	SPECIMEN DETAILS		ORDERED BY	
V	Mancl Univer		NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018		
	FOR ACADEMIC PURPOSES ONLY - NO	DT FOR CLINICAL USE					
✓	Bisoprolol Zebeta	metabolized in the CYP3A4 with smalle	guidance: Bisoprolol is elimina liver and 50% being excreted vi r contribution from CYP2D6. Li ibition are not affected by CYP	a the kidneys unchanged mited studies suggest tha	l. Bisoprolol is pr at bisoprolol pla	redominantly metabolized by sma concentrations and its	
	Brexpiprazole	Normal Sensitivit	ty to Brexpiprazole (CYP2D	6: Normal Metabolize	r)	ACTIONABL	
-	Rexulti		e prescribed at standard label- a favorable response is achieve	-	nd administration	n. Careful titration is	
		daily maintenance o	nt of Major Depression Disorde loses and maximum recommer ing dose is 1 mg once daily. Th ectively.	nded dose are 1-2 mg and	d 3 mg, respectiv	vely. Schizophrenia: the	
		coadministered. Ad	<u>vith comedications</u> : reduce dos minister a quarter of the usual o YP3A4 inhibitor are coadministe	dose if both a strong/mo	derate CYP2D6 i	nhibitor and a	
\checkmark	Brivaracetam	Normal Sensitivit	ty to Brivaracetam (CYP2C1	9: Rapid Metabolizer)		ACTIONABL	
	Briviact		narily metabolized by hydrolysis tam can be prescribed at the st			which is mediated by	
\checkmark	Buprenorphine	Normal Response	e to Buprenorphine			INFORMATIVE	
	Butrans, Buprenex	Buprenorphine is pr The effects of genet concomitant use of increase or prolong	guidance: no genetically guide rimarily metabolized by CYP3A4 tic variants in these enzymes or buprenorphine with all CYP3A4 adverse drug effects. Monitor decrease buprenorphine levels.	to norbuprenorphine ar its response have not be inhibitors may result in	nd by UGT enzyn een studied. Pol an increase in th	nes (mainly UGT1A1 and 2B7). ypharmacy guidance: The e drug levels, which could	
\checkmark	Bupropion	Normal Response	e to Bupropion (CYP2B6: N	ormal Metabolizer)		INFORMATIVE	
	Wellbutrin, Zyban, Aplenzin, Contrave	therapeutic effects of or non-genetic factor	olized to its active metabolite h of bupropion when used as a sr ors are present, individuals who oxybupropion. Bupropion can	moking cessation agent c are CYP2B6 normal met	or as an antidepr abolizers are not	essant. Unless other genetic t expected to have lower	
\checkmark	Candesartan	Normal Sensitivit	y to Candesartan Cilexetil			ACTIONABLE	
-	Atacand	gastrointestinal trac	guidance: Candesartan cilexeti t during absorption. Candesart Genetic variability of the cytoc	an undergoes minor hep	atic metabolism	by O-deethylation to an	

	A Manch	lector	PATIENT INFORMATION	SPECIMEN DETAILS		ORDERED BY
	FOR ACADEMIC PURPOSES ONLY - NO	sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX: Image: Compare the second secon	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018	
./	Carbamazepine	Normal Response	e to Carbamazepine			INFORMATIVI
V	Tegretol, Carbatrol, Epitol	Pharmacogenetic g be used to identify p syndrome, Stevens therapeutic window, metabolized by epo plasma concentration CYP3A5*1/*1 or *1/* dosage of carbamaz	guidance: Genotype results obt patients at risk for severe cutand Johnson syndrome (SJS) and to: is extensively metabolized by (xide hydrolase (EPHX1) to an in ons are 30% higher in individual 3 genotypes. The clinical impace tepine should be decreased in p the carbamazepine levels, and do	eous adverse reactions su kic epidermal necrolysis (CYP3A4/5 to its active ep active metabolite. Prelim s with the CYP3A5*3/*3 (ct of this change is poorly patients receiving CYP3A	uch as anticonvu (TEN). Carbama: ioxide metaboli iinary studies in genotype comp y documented. 4 inhibitors. Enz	erformed in this patient cannot ulsant hypersensitivity zepine, a drug with a narrow te, which is further dicate that carbamazepine ared to those with Polypharmacy guidance: The yme-inducing drugs
	Cariprazine	Normal Response	e to Cariprazine			ACTIONABLE
	Vraylar	Genetic variants of C No geneticallly guid may affect cariprazir	juidance: Cariprazine is extensi CYP2D6 do not have clinically re ed dosing recommendations ar ne plasma concentrations. Carip e used concomitantly. Concomi nded.	elevant effect on pharma e available. Polypharma razine dose may have to	cokinetics of car acy guidance: C be reduced to	riprazine and its metabolites. CYP3A4 inhibitors or inducers half if cariprazine and a strong
\checkmark	Carvedilol	Normal Sensitivit	y to Carvedilol (CYP2D6: N	ormal Metabolizer)		ACTIONABLE
	Coreg		escribed at standard label-reco monitoring until a favorable res	-	dministration. C	areful titration is
	Caspofungin	Normal Response	e to Caspofungin			ACTIONABLE
-	Cancidas	undergoes also spoi dominant mechanis are available. Polyp rifampin, efavirenz, i	juidance: Caspofungin is cleare ntaneous chemical degradation m influencing plasma clearance harmacy guidance: Co-admini nevirapine, phenytoin, or carbar trations which may require dos	. Distribution, rather thar . No genetically guided o stration of caspofungin v nazepine) may result in o	n excretion or bi drug selection o with metabolizir	iotransformation, is the r dosing recommendations ng enzyme inducers (e.g.,
\checkmark	Celecoxib	Normal Sensitivit	y to Celecoxib (CYP2C9: Nc	ormal Metabolizer)		ACTIONABLE
	Celebrex	Celecoxib can be pro	escribed at standard label-reco	nmended dosage and ac	dministration.	
\	Chlorpromazine	Normal Sensitivit	y to Chlorpromazine (CYP2	D6: Normal Metaboli	zer)	INFORMATIVE
-	Thorazine	-	netabolized by CYP2D6, CYP3A commended-dosage and admir	-		- ·
\checkmark	Chlorpropamide	Normal Sensitivit	y to Chlorpropamide (CYP2	C9: Normal Metaboli	zer)	INFORMATIVE
	Diabenese	The patient's genotype predicts a normal exposure to chlorpropamide, and this drug can be prescribed at recommended dosage and administration (dose titration in response to plasma levels of glucose/glycosyla hemoglobin).				

	A Manch	loctor	PATIENT INFORMATION	SPECIMEN DETAILS		ORDERED BY
	FOR ACADEMIC PURPOSES ONLY - NOT	sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX: 1/1/1900	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018	
	Clobazam	Normal Sensitivit	ty to Clobazam (CYP2C19: Ra	pid Metabolizer)		ACTIONABL
v	Onfi	The genotype result function. Rapid and metabolite of cloba: prescribed. Therefor standard label-reco clinical efficacy and concentrations of cl Recommended dail	t predicts a rapid or an ultra-rapid ultra-rapid metabolizers have a zam. However, there is insufficier re, the dosing recommendation f mmended dosage and administr tolerability. Do not proceed with obazam and its active metabolite y dosing: ≤30 kg body weight: st ie 10 mg, day 7: 20 mg and day 1	d metabolizer phenotyp higher capacity to meta nt data to allow calculat for normal metabolizers ation. Individualize dosi dose escalation more r e require 5 and 9 days, r arting dose 5 mg; day 7	bolize N-desr ion of dose ac is proposed. ing within eac rapidly than w respectively, to	nethylclobazam, the active djustment when clobazam is Clobazam can be prescribed at h body weight group, based on eekly, because serum o reach steady state.
	Clonazepam	Normal Response	e to Clonazepam			INFORMATIV
	Klonopin	Polypharmacy guid	guidance: No genetically guided dance: clonazepam is extensively etyltransferases. This drug should	y metabolized by CYP3A	A4 to an amin	o metabolite that is further
	Clonidine	Normal Sensitivit	y to Clonidine (CYP2D6: Noi	rmal Metabolizer)		INFORMATIVI
	Карvау	remainder undergoi CYP3A and CYP1A2	0% of an orally administered dos ing hepatic metabolism. CYP2D6 . Clonidine can be prescribed at s lized according to the therapeuti	plays a major role in cle standard label recomme	onidine oxida ended-dosage	tive metabolism, followed by
\	Codeine	Normal Response	e to Codeine (CYP2D6: Norm	nal Metabolizer)		ACTIONABLE
	Codeine; Fioricet with Codeine	Codeine can be pres	scribed at standard label-recomr	nended dosage and ad	ministration.	
	Colchicine	Normal Response	e to Colchicine			INFORMATIVE
-	Mitigare	absorbed dose in el metabolic pathway this transporter is in indicate a lack of an with familial Medite recommendations. I enzyme and the P-c toxicity. Inhibition o threatening or fatal	guidance: Colchicine in eliminate iminated unchanged in urine, less for colchicine. Colchicine is a sub nportant in its disposition. Colchi effect of CYP3A4 or ABCB1 gene rranean fever (FMF). There are no Polypharmacy guidance: Becau glycoprotein efflux transporter, in f both CYP3A4 and P-gp by dual colchicine toxicity due to signific d inhibitors of CYP3A4 or P-glyco	ss than 20% is metaboliz ostrate of P-glycoprotein icine has a narrow thera etic polymorphisms on o available genetically- <u>c</u> use colchicine is a substr ihibition of either of the l inhibitors such as clarif cant increases in system	zed by CYP3A n (encoded by peutic index. clinical respor guided drug s rate for both t se pathways r thromycin has ic colchicine le	4. Glucuronidation is also a ABCB1 gene) and its efflux by Preliminary and limited studies use to colchicine in individuals election or dosing he CYP3A4 metabolizing may lead to colchicine-related been reported to produce life-
	Cyclobenzaprine	Normal Response	e to Cyclobenzaprine			INFORMATIVE
-	Flexeril, Amrix	Pharmacogenetic g Cyclobenzaprine is e CYP1A2, and to a le	guidance: No genetically guided excreted primarily as a glucuroni sser extent CYP2D6. Due to the r of this enzyme is not of concern i	de via the kidneys, and ninor involvement of C	as an N-deme	ethylated metabolite by CYP3A4,



	🐼 Mancheste		PATIENT INFORMATION	ORDERED BY	
	FOR ACADEMIC PURPOSES ONLY - NOT	sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:		1900 1900 2018
✓	Dabigatran	Normal Response	e to Dabigatran		INFORMATIVE
	Etexilate Pradaxa	dabigatran etexilate also conjugated to f CYP450 enzymes. D polymorphism of th Polypharmacy gui moderate renal imp ketoconazole can b Consider reducing t with other P-gp inh <u>2-Treatment of DVT</u>	is converted to its active form of form pharmacologically active a abigatran etexilate is a substrate e ABCB1 gene (2677G>T/A and dance: <u>1-Reduction in Risk of St</u> airment (CrCl 30-50 mL/min), cc e expected to produce dabigatra he dose of dabigatran to 75 mg ibitors. In patients with CrCl<30	dabigatran by esterases. A sn cyl glucuronides. Dabigatran e of the efflux transporter P-c 3435 C>T) do not appear to ocke and Systemic Embolism oncomitant use of the P-gp in an exposure similar to that o twice daily. Dose adjustmen mL/min, avoid use of concor	-
√	Darifenacin Enablex		e to Darifenacin (CYP2D6: N	-	ACTIONABLE
	Desipramine Norpramin		y to Desipramine (CYP2D6: prescribed at standard label-re		ACTIONABLI
\	Desvenlafaxine Pristiq		y to Desvenlafaxine (CYP2E be prescribed at standard label-		ACTIONABLE
\	Deutetrabenazine Austedo	For treating chorean required. The first w	-	s disease: Individualization of daily then slowly titrate at v	of dose with careful weekly titration is veekly intervals by 6 mg per day to a
	Dexmethylphenid ate	Good Response t	o Dexmethylphenidate (CO	MT: High/Normal COMT	Activity) INFORMATIVE
	Focalin		ding to the needs and response		thylphenidate. Dosage should be Ild be initiated in small doses, with
\	Dextroamphetami ne	Normal Exposure	to Dextroamphetamine (C	YP2D6: Normal Metaboli	zer) INFORMATIVE
	Dexedrine		e can be prescribed at standard o the therapeutic needs and res		and administration. Individualize the

V	FOR ACADEMIC PURPOSES ONLY - NOT	sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018				
	Dextroamphetami		to Dextroamphetamine (CC	MT: High/Normal COMT Activ	vity) INFORMATIVI			
	ne Dexedrine			lihood of response to amphetamin e lowest effective dose, and dosage				
\	Dextromethorpha n / Quinidine	Normal Sensitivit	ty to Dextromethorphan-Q	uinidine (CYP2D6: Normal Me	tabolizer) ACTIONABLI			
	Nuedexta	the dextromethorph	han-quinidine combination to in	a specific inhibitor of CYP2D6-dependerease the systemic bioavailability cording to standard label-recommendered by the standard label-recommendered by the standard label-recommendered by the standard by th	-			
	Diclofenac	Normal Sensitivit	ty to Diclofenac (CYP2C9: N	lormal Metabolizer)	INFORMATIV			
	Voltaren	Individuals with a normal CYP2C9 activity (i.e normal metabolizers) can be prescribed diclofenac according to standard label recommended-dosage and administration.						
	Dihydrocodeine Normal Response to Dihydrocodeine (CYP2D6: Normal Metabolizer)							
	Synalgos-DC	Dihydrocodeine car	n be prescribed at standard labe	el-recommended dosage and admi	nistration.			
	Dolasetron Anzemet	Normal Response	e to Dolasetron (CYP2D6: N	lormal Metabolizer)	INFORMATIV			
	Anzennet	Dolasetron can be p	prescribed at standard label-rec	ommended dosage and administra	ation.			
	Dolutegravir		e to Dolutegravir		ACTIONABL			
	Tivicay, Triumeq	contribution from C have increased plas required for doluted	YP3A. Although UGT1A1 poor ma levels of dolutegravir, these gravir due to genetic variations	nated mainly through metabolism metabolizers or patients taking inh changes are not clinically significa in UGT1A1. Polypharmacy guidar lucers, such as rifampin, may result	ibitors of UGT1A1 activity nt. No dosing adjustments are			
	Donepezil	Normal Response	e to Donepezil (CYP2D6: N	ormal Metabolizer)	INFORMATIV			
	Aricept		rescribed at standard label-reco l a favorable response is achieve	ommended dosage and administrat ed.	tion. Careful titration is			
\	Doxazosin Cardura	Polypharmacy gui	guidance: no genetically guide	d drug selection or dosing recomm d by multiple enzymes. There is lin				
	Dronabinol	Normal Sensitivit	ty to Dronabinol (CYP2C9: I	Normal Metabolizer)	INFORMATIV			
-	Marinol		otype predicts a normal CYP2C9 metabolic activity. Dronabinol can be prescribed at standa osage and administration.					

	Manch Univer	sity	NAME: ACC #:	T INFORMATION Patient 35962 35962 1/1/1900	SPECIMEN DETAILS SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:		ORDERED BY
	FOR ACADEMIC PURPOSES ONLY - NO	T FOR CLINICAL USE					
	Duloxetine	Normal Sensitivi	ty to Dulo	oxetine (CYP2D6:	Normal Metabolizer)		INFORMATIV
	Cymbalta	Duloxetine can be	prescribed	at standard label-red	commended dosage and	administratior).
/	Dutasteride	Normal Respons	e to Duta	steride			INFORMATIV
	Avodart	Polypharmacy gu CYP3A4 inhibitors	i dance: Du on dutaster	tasteride is extensive ide has not been stu		s by CYP3A4 a ential for drug	dations are available. and CYP3A5. The effect of poten -drug interactions, use caution
/	Edoxaban	Normal Respons	e to Edox	aban			INFORMATIV
	Savaysa	via hydrolysis (mec efflux transporter F SLCO1B1. Prelimina does not affect edd	liated by ca ge and its ary studies oxaban pha	rboxylesterase 1), cc active metabolite (f indicate that the 521 rmacokinetics. Poly	njugation, and oxidation ormed by carboxylesteras C single nucleotide polyr	by CYP3A4. Ed se 1) is a subst norphism (rs4 pid the concor	ne. There is minimal metabolism doxaban is a substrate of the rate of the uptake transporter 149056) of the SLCO1B1 gene nitant use of edoxaban with
/	Eprosartan	Normal Sensitivi	ty to Epro	osartan			ACTIONABL
	Teveten	Eprosartan is not m	netabolized	by the cytochrome		ariability of the	narily as unchanged compound. e cytochrome P450 genes is not stments are available.
1	Eslicarbazepine	Normal Respons	e to Eslica	arbazepine			INFORMATIV
	Aptiom	be used to identify syndrome, Stevens converted by a red excretion unchange are available. Poly	patients at -Johnson s uctase to it ed and as a oharmacy	risk for severe cutar yndrome (SJS) and to s active metabolite, glucuronide conjug	eous adverse reactions s oxic epidermal necrolysis eslicarbazepine. Eslicarbaz ate. No genetically guide esence of enzyme-inducir	uch as anticor (TEN). Eslicarb zepine is elimi d drug selectio	azepine acetate (prodrug) is
/	Ethosuximide	Normal Respons	e to Etho	suximide			INFORMATIV
	Zarontin	Pharmacogenetic Polypharmacy gu with caution when	guidance: i dance: eth prescribed	No genetically guide osuximide is extensi with CYP3A4 inhibite		BA4, and there ncrease ethose	dations are available. fore this drug should be used uximide clearance, and higher
/	Ezogabine	Normal Respons	e to Ezog	abine			INFORMATIV
	Potiga	metabolite, no dos metabolized prima	e adjustme rily via gluc	nt is necessary in the uronidation (by UGT	se individuals. Polyphar 1A4 and UGT1A1) and ac	macy guidane etylation (by I	e exposure of ezogabine active ce: Ezogabine is extensively NAT2). There is no evidence of in these metabolizing enzymes



	7) Mana	hester	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY			
V	FOR ACADEMIC PURPOSES ONLY - N	rsity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:		/1/1900 /1/1900 /8/2018			
./	Febuxostat	Normal Response	e to Febuxostat		INFORMATIVI			
V	Uloric	Pharmacogenetic of metabolized both b cytochrome P450 en metabolized to an a are no available ger administration of pu	guidance: Febuxostat is eliminat y glucuronidation and oxidative nzymes (CYPs): CYP1A2, CYP2C8 acyl glucuronide, primarily by UG netically-guided drug selection o	pathways. The oxidative m and CYP2C9 as well as oth T1A1 with contributions fr r dosing recommendation ibitor, with substrate drug	polism and renal excretion. The drug is netabolism of this drug involves several ner non-CYP enzymes. Febuxostat is also rom UGT1A3, UGT1A9 and UGT2B7. There is. Polypharmacy guidance: Concomitant is such as theophylline, azathioprine or			
	Felbamate	Normal Response	e to Felbamate		INFORMATIVE			
	Felbatol	Polypharmacy gui 50% is present as m minor for drug elim enzyme-inducing au	netabolites and conjugates. Felba ination when the drug is given a	ed felbamate dose appear mate is a substrate of CYF s a monotherapy. This pat n a 30-50% decrease in fe	s unchanged in urine, and an additional P3A4 and CYP2E1, but these pathways are hway is enhanced by concomitant use of Ibamate plasma concentrations. Felbamate			
√	Fesoterodine Toviaz		Normal Sensitivity to Fesoterodine (CYP2D6: Normal Metabolizer) ACTION Fesoterodine can be prescribed at standard label-recommended dosage and administration.					
	Finasteride	Normal Response	e to Finasteride		INFORMATIVI			
	Proscar	Polypharmacy gui moderate CYP3A4 i		metabolized in humans by been studied. Because of	y CYP3A4. The effects of potent or the potential for drug-drug interactions,			
√	Flecainide	Normal Sensitivit	ty to Flecainide (CYP2D6: No	ormal Metabolizer)	ACTIONABLE			
	Tambocor	Flecainide can be protected the standard precau		nmended dosage and adn	ninistration. No action is needed besides			
	Flibanserin	Normal Exposure	e to Flibanserin (CYP2C19: Ra	pid Metabolizer)	ACTIONABLE			
	Addyi	Flibanserin is prima	rily metabolized by CYP3A4 and, to have a normal clearance and a	to a lesser extent, by CYP2	ve sexual desire disorder (HSDD): 2C19. The genotype results predict that the nserin. Use label-recommended dosage and			
\checkmark	Fluconazole	Normal Response	e to Fluconazole		ACTIONABLE			
-	Diflucan	approximately 80% pharmacokinetics o or dosing recomme CYP2C9 and CYP2C therapeutic window	of the administered dose appear f fluconazole is markedly affected indations are available. Polyphar 19 enzymes. Fluconazole treated	ring in the urine as unchar d by reduction in renal fur macy guidance: Flucona: patients who are concom 19 or CYP3A4 should be n	eliminated primarily by renal excretion, with nged drug and 11% as metabolites. The nction. No genetically guided drug selection zole is a moderate inhibitor of CYP3A4, nitantly treated with drugs with a narrow nonitored. The enzyme inhibiting effect of half-life.			
	Fluoxetine	Normal Sensitivit	ty to Fluoxetine (CYP2D6: No	ormal Metabolizer)	INFORMATIVE			
-	Prozac, Sarafem	Fluoxetine is metab	olized to its active metabolite no	rfluoxetine and to other n	netabolites by multiple enzymes including dard label-recommended dosage and			
	Powered By Translational							

$\mathbf{\Lambda}$	7) Mane	hester	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
	FOR ACADEMIC PURPOSES ONLY - N	rsity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX: Image: Compare the second secon	SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018	
1	Fluphenazine	Normal Sensitivit	y to Fluphenazine (CYP2D	5: Normal Metabolizer)	INFORMATIVI
	Prolixin	Fluphenazine can be cautiously with oral	e prescribed at standard label r or parenteral fluphenazine hyc t, an equivalent dose of fluphe	ecommended-dosage and administra Irochloride. When the pharmacologic nazine decanoate (IM or SC) may be	ation. Therapy must be initiated an effects and an appropriate
/	Flurbiprofen Ansaid		y to Flurbiprofen (CYP2C9)	Normal Metabolizer) ecommended dosage and administra	ACTIONABLE
	Fluvastatin	Normal Myopath	y Risk (SLCO1B1: Decreased	Function)	INFORMATIVE
v	Lescol	Fluvastatin plasma o present, fluvastatin specific guidelines.	concentrations are not expected can be prescribed at standard l	d to increase, and unless other genet DA-recommended starting doses an factors include advanced age (≥65),	ic or circumstantial risk factors are Id adjusted based on disease-
	Fluvastatin	Normal Sensitivit	y to Fluvastatin (CYP2C9: N	lormal Metabolizer)	ACTIONABLE
	Lescol	present, fluvastatin specific guidelines.	can be prescribed at standard l Other adverse events and pred	d to increase, and unless other genet DA-recommended starting doses an isposing factors include advanced ag 22C9 inhibitors, ABCG2 inhibitors, and	nd adjusted based on disease- e (≥65), diabetes, hypothyroidism,
	Fluvoxamine	Normal Sensitivit	y to Fluvoxamine (CYP2D6	: Normal Metabolizer)	ACTIONABLE
	Luvox		prescribed at standard label re a favorable response is achiev	ecommended-dosage and administra ed.	tion. Careful titration is
	Fondaparinux	Normal Response	e to Fondaparinux		INFORMATIVE
	Arixtra	CYPs, and therefore profiles. no genetica concomitant use of may enhance the ris	genetic variations in these me ally guided drug selection or do fondaparinux with aspirin or N	ninated unchanged through renal exc tabolizing enzymes are not expected osing recommendations are available SAIDS may enhance the risk of hemo tion of therapy with fondaparinux un ige.	to affect its efficacy or toxicity Polypharmacy guidance: The prhage. Discontinue agents that
	Fosaprepitant	•	e to Fosaprepitant		ACTIONABLE
	Emend-i.v	intravenous adminis metabolism via N- a CYP1A2 and CYP2C dosing recommend inhibitors, a significa should be avoided v a loss of efficacy. Th inhibitor, and an inc	stration. Its antiemetic effects a and O-dealkylations. These path 19. The drug is also glucuronid ations are available. Polypharr antly increased exposure of api with fosaprepitant. Strong CYP3 tese drugs should also be avoid ducer of CYP3A4 and an induce while others should be closely r	rodrug of aprepitant which is rapidly re attributable to aprepitant. Aprepita mways are primarily catalyzed by CYP ated by UGT1A4 and UGT1A3. No ge nacy Guidance: In presence of mode repitant is expected which may lead t BA4 inducers can significantly decreas led with fosaprepitant. Aprepitant is a r of CYP2C9. Some substrates of thes nonitored and their doing adjusted w	ant undergoes extensive 3A4 with minor involvement from inetically guided drug selection or erate and strong CYP3A4 o adverse reactions. These drugs se aprepitant exposure resulting in a moderate (dose-dependent) se enzymes are contraindicated



	7) Mana	hastan	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
V	FOR ACADEMIC PURPOSES ONLY - N	V	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX: Image: Comparison of the second	SPECIMEN TYPE: COLLECTION DATE: 1/1/1 RECEIVED DATE: 1/1/1 REPORT DATE: 2/8/2	900
	Fosphenytoin	Normal Sensitiv	ity to Fosphenytoin (CYP2C	9: Normal Metabolizer)	ACTIONABL
	Cerebyx		ng dose and a standard mainter		bolizer. Fosphenytoin can be prescribed and serum concentrations 7-10 days
	Gabapentin	Normal Respons	se to Gabapentin		INFORMATIVE
	Neurontin	Pharmacogenetic Polypharmacy gu Genetic variations	guidance: no genetically guide idance: Gabapentin is eliminate	d primarily through renal excre are not expected to affect its ef	ommendations are available. etion and is not metabolized by CYPs. fficacy or toxicity profiles. Gabapentin
	Galantamine	Normal Sensitiv	ity to Galantamine (CYP2D6	: Normal Metabolizer)	INFORMATIVE
	Razadyne	Galantamine can b with weekly titratic	ecommended dosage and adm	inistration. Individualization of dose	
	Glimepiride	Normal Sensitiv	ity to Glimepiride (CYP2C9:	Normal Metabolizer)	ACTIONABL
-	Amaryl		prescribed according to standa a levels of glucose/glycosylated	-	e and administration (dose titration in
	Glipizide	Normal Sensitiv	ity to Glipizide (CYP2C9: No	rmal Metabolizer)	INFORMATIVE
	Glucotrol		escribed according to standard a levels of glucose/glycosylated	÷	nd administration (dose titration in
	Glyburide	Normal Sensitiv	ity to Glyburide (CYP2C9: N	ormal Metabolizer)	ACTIONABLE
	Micronase	, j	rescribed according to standarc a levels of glucose/glycosylated	5	and administration (dose titration in
	Granisetron	Normal Respons	se to Granisetron		ACTIONABLE
	Sancuso, Sustol	desmethylgraniset women reported a clearance of the dr within the CYP3A4 an association with is unclear and no <u>c</u> Inducers or inhibite an in vivo pharmac of granisetron with	n increased granisetron clearand ug in subjects with the CYP3A5* or ABCB1 genes, had no effect or granisetron efficacy and ABCB genetically guided drug selection ors of CYP1A1 and CYP3A4 enzy cokinetic interaction with strong	P1A1. A preliminary pharmacol is in carriers of the CYP1A1*2A 3/*3 genotype. The same stud on granisetron clearance while genetic polymorphisms. The or dosing recommendations mes may affect the clearance of CYP3A4 inhibitors such as keto	sygranisetron and 9- kinetic study conducted in pregnant a increased function allele and a lower y showed that genetic polymorphisms other reports in cancer patients found significance of these preliminary findings are available. Polypharmacy guidance: of granisetron. However, the potential for poconazole is not known. Administration ranisetron clearance and the clinical



	7 Manah	noctor	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY		
	FOR ACADEMIC PURPOSES ONLY - NOT	sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:		/1/1900 /1/1900 /8/2018		
	Guanfacine	Normal Respons	o to Guanfacino		INFORMATIV		
V	Intuniv	Pharmacogenetic or dosing recomme response and toler should be reduced ketoconazole, itrac should be increase recommended dos	guidance: Guanfacine is predon endations are available and guan ability of the individual patient. F to one half of the standard do onazole, indinavir, ritonavir, nefa d to the standard recommended e when used in combination with b. When the CYP3A4 inducer is di	facine extended-release sh Polypharmacy guidance: T se when co-medicated wit zodone). When the strong dose. Guanfacine dose sho a strong CYP3A4 inducer	(P3A4. No genetically guided drug selection nould be titrated based on the clinical The dose of guanfacine extended-release h a strong CYP3A4 inhibitor (e.g., CYP3A4 inhibitor is discontinued, the dose buld be increased up to double the (e.g., phenytoin, carbamazepine, rifampin,		
	Haloperidol	Normal Sensitivi	ty to Haloperidol (CYP2D6: I	Normal Metabolizer)	ACTIONABL		
-	Haldol	Haloperidol can be prescribed at standard label-recommended dosage and administration. Careful titration is recommended until a favorable response is achieved.					
	Hydromorphone	Normal Respons	e to Hydromorphone		INFORMATIV		
	Dilaudid, Exalgo	No genetically guid	e. Hydromorphone is not metabolized by to affect its efficacy or toxicity profiles. nd administration.				
\	Ibuprofen	Normal Sensitivi	ty to Ibuprofen (CYP2C9: No	ormal Metabolizer)	INFORMATIV		
	Advil, Motrin	Individuals with a r label recommende	scribed ibuprofen according to standard				
	lloperidone	Normal Sensitivity to Iloperidone (CYP2D6: Normal Metabolizer)					
-	Fanapt	Iloperidone can be prescribed at standard label-recommended dosage and administration. Iloperidone must be titra slowly from a low starting dose to avoid orthostatic hypotension. If patients taking iloperidone experience symptom could indicate the occurrence of cardiac arrhythmias (e.g., dizziness, palpitations, or syncope), the prescriber should initiate further evaluation, including cardiac monitoring.					
	Indomethacin	Normal Sensitivi	ty to Indomethacin (CYP2C9	: Normal Metabolizer)	INFORMATIV		
	Indocin	Indomethacin can be prescribed at standard label recommended-dosage and administration.					
\	Irbesartan	Normal Sensitivi	ty to Irbesartan (CYP2C9: No	ormal Metabolizer)	INFORMATIV		
	Avapro	Irbesartan can be prescribed at standard label-recommended dosage and administration.					
\	Isavuconazonium	Normal Respons	e to Isavuconazonium		ACTIONABL		
	Cresemba	butylcholinesterase and Common gene exposure. No gene	tic polymorphism of these meta tically guided drug selection or c	zole. Isavuconazole is exter bolizing enzymes gene are losing recommendations a	bidly hydrolyzed in plasma by nsively metabolized CYP3A4 and CYP3A5 not expected to affect isavuconazole re available. Polypharmacy guidance: inhibitors or inducers contraindicated.		

	7) Monal	octor	PATIENT INFORMATION	SPECIMEN DETAILS	5	ORDERED BY			
V	FOR ACADEMIC PURPOSES ONLY - NOT	sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018				
						ACTIONADU			
V	Itraconazole <i>Sporanox</i>	metabolite is hydro concentrations of the recommendations a may decrease the bi Therefore, administr should be avoided 2 bioavailability of itra Itraconazole inhibit in increased plasma elevated plasma cor using concomitant r	guidance: Itraconazole is extensive itraconazole, which has in vituris metabolite are about twice the re available. Polypharmacy guid to availability of itraconazole and tration of potent CYP3A4 inducers weeks before and during treats aconazole and these drugs shout the metabolism of drugs metabolism of these drugs and concentrations of these drugs and these drugs are and the are are and the are are and the are are are are are are are are are ar	ro antifungal activity co nose of itraconazole. No idance: Coadministratic I hydroxy-itraconazole to rs with itraconazole is no ment with itraconazole. Id be used with caution olized by CYP3A4 or tra- and/or their active meta- plong both therapeutic	mparable to it genetically guon of itraconaz o such an exter ot recommenc Potent CYP3A when coadmi insported by P bolite(s) when and adverse ef	raconazole; trough plasma uided drug selection or dosing cole with potent CYP3A4 inducers ent that efficacy may be reduced. Ided and the use of these drugs 4 inhibitors may increase the nistered with this antifungal. P-glycoprotein, which may result they are coadministered. These			
	Ketoprofen	Normal Response	Normal Response to Ketoprofen						
	Orudis	Pharmacogenetic guidance: Ketoprofen is primarily eliminated by glucuronidation (by UGT1A3, UGT1A9 and UGT2B7) and no major implication of CYP2C9 in the metabolism of this drug has been demonstrated. No genetically guided drug selection or dosing recommendations are available.							
	Ketorolac	Normal Response	e to Ketorolac			INFORMATIVE			
	Toradol	Pharmacogenetic g	guidance: Ketorolac is metaboli			s) and oxidation but the enzymes or dosing recommendations are			
	Labetalol	Normal Response	e to Labetalol			INFORMATIVE			
	Normodyne, Trandate	Pharmacogenetic of metabolites. Prelimi -fold higher in Chine clinical impact of thi	juidance: Labetalol is extensive	ing a single 200-mg or 9 *2/*2 genotype than t rmacy guidance: Cimet	al dose, labeta hose with the	lol plasma concentrations are 2.9 CYP2C19 *1/*1 genotype. The			
√	Lacosamide	Normal Sensitivit	y to Lacosamide (CYP2C19:	Rapid Metabolizer)		INFORMATIVE			
	Vimpat	CYP2C19 is partly involved in the metabolism of lacosamide, along with CYP2C9 and CYP3A, and this drug can be prescribed at standard label-recommended dosage and administration.							
	Lamotrigine	Normal Response	e to Lamotrigine			INFORMATIVE			
-	Lamictal	Pharmacogenetic of be used to identify p syndrome, Stevens- glucuronidation, wh insufficient studies of response. No geneti Enzyme-inducing dr maintain therapeuti lamotrigine levels an	guidance: Genotype results obta batients at risk for severe cutane Johnson syndrome (SJS) and tox ich is mediated primarily by UG documenting the impact of gene ically guided drug selection or d rugs increase lamotrigine clearar c concentrations. Coadministrati	eous adverse reactions s kic epidermal necrolysis T1A4 with some contrib etic polymorphisms of t losing recommendation nce significantly, and his ion of valproic acid, an gine adverse effects (ne	uch as anticor (TEN). Lamotr oution from UC hese metaboli is are available gher doses of inhibitor of UC urological and	igine is metabolized by 6T1A1 and UGBT2B7. There are zing enzymes on lamotrigine e. Polypharmacy guidance: this drug are required to 6T enzymes, increases cutaneous). A low starting dose			

	7) Manch	actor	PATIENT INFORMATION	SPECIMEN DETAILS		ORDERED BY		
	FOR ACADEMIC PURPOSES ONLY - NOT	•	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018			
/	Leflunomide	Normal Sensitiv	ity to Leflunomide (CYP2C19	· Rapid Metabolizer)		INFORMATIN		
	Arava	Leflunomide can b count (CBC) and liv	e prescribed according to standa ver function parameters should b ne initial 6 months of therapy. Blo	rd label-recommended e checked no more than	6 months be	dministration. Full blood cell fore beginning treatment, and		
	Lesinurad	Normal Sensitiv	ity to Lesinurad (CYP2C9: No	ormal Metabolizer)		ACTIONABL		
	Zurampic		he patient's genotype predicts a normal CYP2C9 metabolic activity. Lesinurad can be prescribed at star ecommended dosage and administration.					
	Levetiracetam	Normal Respons	se to Levetiracetam			INFORMATIV		
	Keppra	Polypharmacy gu	e guidance: No genetically guide idance: Levetiracetam is minima ed in urine. Coadministration of e ma levels.	lly metabolized by non-	CYP enzymes	(esterases) and is primarily		
	Levomilnacipran	Normal Respons	se to Levomilnacipran			INFORMATIV		
	Fetzima	by CYP3A4, with m in urine as unchan expected to have a recommendations	E guidance: Levomilnacipran is m ninor contributions by CYP2C8, C ged levomilnacipran, and 18% as a significant impact on levomilna- are available. Polypharmacy gu th strong CYP3A4 inhibitors, such	YP2C19, CYP2D6, and CY N-desethyl levomilnaci cipran exposure. no gene idance : the daily levomi	P2J2. More the pran. Genetic etically guided linacipran dos	han 58% of the dose is excreted polymorphisms of CYPs are not d drug selection or dosing se should not exceed 80 mg when		
	Levorphanol	Normal Respons	se to Levorphanol			INFORMATIV		
	Levo Dromoran	studies documenti no genetically guid	Pharmacogenetic guidance: Levorphanol is metabolized by glucuronidation which is mediated by studies documenting the impact of genetic polymorphisms of this metabolizing enzyme on levorph no genetically guided drug selection or dosing recommendations are available. Polypharmacy gui inducing drugs are expected to increase levorphanol clearance significantly.					
	Lisdexamfetamine	Normal Exposur	re to Lisdexamfetamine (CYP	2D6: Normal Metabo	lizer)	INFORMATIV		
	Vyvanse		can be prescribed at standard la to the therapeutic needs and res		ge and admin	istration. Individualize the		
	Lisdexamfetamine	Good Response	to Lisdexamfetamine (COM	Г: High/Normal COM	T Activity)	INFORMATIV		
	Vyvanse		type result predicts a higher likel tered at the lowest effective dose					
	Losartan	Normal Respons	se to Losartan (CYP2C9: Nor	mal Metabolizer)		INFORMATIV		
_	Cozaar, Hyzaar		blized to its active metabolite by an and its active metabolite. Losa					

	7) Monal	noctor	PATIENT INFORMATION	SPECIMEN DETAILS	;	ORDERED BY
	FOR ACADEMIC PURPOSES ONLY - NO	e e	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018	
	Loxapine	Normal Response	e to Loxapine			INFORMATIV
	Loxitane, Adasuve	Pharmacogenetic g metabolites formed. contributions from C these metabolizing e dosing recommenda concurrent use of Lc antidepressants, ger can increase the risk reduction/modificati	Juidance: Loxapine is metabolize Loxapine metabolism occurs via CYP3A4, CYP2D6 and FMO. There enzymes on Loxapine disposition ations. Polypharmacy guidance: exapine with other CNS depressar heral anesthetics, phenothiazines, of respiratory depression, hypoto ion of CNS depressants if used co- th other anticholinergic drugs can	hydroxylation and oxi are no studies docum and there are no avail Loxapine is a central in the (<i>e.g.</i> , alcohol, opioi sedative/hypnotics, m ension, profound seda procomitantly with Loxa	dation catalyze enting the effe lable genetical nervous system d analgesics, b nuscle relaxants tion, and synco apine. Loxapine	ed by CYP1A2 along with ect of genetic polymorphisms o ly-guided drug selection or n (CNS) depressant. The enzodiazepines, tricyclic s, and/or illicit CNS depressants ope. Therefore, consider dose has anticholinergic activity and
	Lurasidone	Normal Response	e to Lurasidone			ACTIONABL
	Latuda	available. Polyphari increase in lurasidor not be administere with moderate CYP3 strong inducers of	guidance: Lurasidone is metaboli. macy guidance: The concomitan ne plasma concentrations, which o ed with strong CYP3A4 inhibitor BA4 inhibitors. Monitor patients re CYP3A should not be administe nducer, it may be necessary to inc	t use of lurasidone wit could increase or prolo rs. Lurasidone dose sh eceiving lurasidone an ered with lurasidone.	h all CYP3A4 in ong adverse dr ould not excee d any CYP3A4 If lurasidone i	hibitors may result in an ug effects. Lurasidone should ed 40 mg when administered inhibitor. Rifampin or other s used concomitantly with a
V	Maprotiline Ludiomil		y to Maprotiline (CYP2D6: No			INFORMATIV
	Meloxicam	Normal Sensitivit	y to Meloxicam (CYP2C9: No	rmal Metabolizer)		INFORMATIV
	Mobic	-	concentrations are not expected t ge and administration.	o be altered. Meloxica	m can be pres	cribed at standard label-
✓	Memantine Namenda	hepatic metabolism metabolite). CYP450 documenting the eff response. No geneti Memantine is predo not expected to inte of drugs that use the	e to Memantine Guidance: Memantine is excreted to three inactive metabolites (N- enzymes do not play a significar fects of genetic variability in meta cally guided drug selection or do minantly renally eliminated, and o eract with memantine. Because me e same renal cationic system, incl , and nicotine, could potentially re	glucuronide, 6hydro nt role in the metabolis abolizing enzymes or co using recommendation drugs that are substrate emantine is eliminated uding hydrochlorothia	xy metabolite, sm of memanti organic cationic s are available. tes and/or inhi l in part by tub ızide, triamtere	and 1-nitroso-deaminated ne. There are no studies transporters on memantine Polypharmacy Guidance: bitors of the CYP450 system are ular secretion, coadministration ne, metformin, cimetidine,
	Meperidine	Normal Response	e to Meperidine			INFORMATIV
V	Demerol	Pharmacogenetic g is metabolized to no variants in these enz meperidine metabol ritonavir, meperidine these findings, the ri	guidance: no genetically guided o prmeperidine by multiple CYPs, in symes have not been studied. Po lism is increased resulting in high e's exposure is significantly reduc isk of narcotic-related adverse eff tions of normeperidine suggest a	cluding CYP2B6, CYP3 lypharmacy guidance er levels of its neuroto ed while normeperidir fects from this combin	A4, and CYP2C : In patients ta ixic metabolite ne concentratic ation appears	lations are available. Meperidine (19. The effects of genetic aking strong CYP inducers , normeperidine. In presence of ons are increased. Based on to be minimal. However,

$\mathbf{\Lambda}$	🖓 Manch	nester	PATIENT INF	ORMATION	SPECIMEN DETAILS		ORDERED BY	
V	Univer	sity	NAME: Patier ACC #: 35962 DOB: 1/1/1 SEX:	2	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018		
	FOR ACADEMIC PURPOSES ONLY - NOT	FOR CLINICAL USE						
	Metaxalone Skelaxin	CYP2D6, CYP2E1, ar	guidance: Meta nd CYP3A4. Ger	axalone is extensive netic polymorphism	ely metabolized by muss of these enzymes ar recommendations ar	e unlikely to a		
	Methadone	Normal Sensitivit	y to Methado	one (CYP2B6: No	rmal Metabolizer)			INFORMATIV
	Dolophine	Methadone can be precautions.	prescribed at st	andard label-recor	nmended dosage. No	action is need	ded besides the s	tandard
	Methocarbamol	Normal Response	e to Methoca	rbamol				INFORMATIV
	Robaxin		metabolism of		abolized via dealkylati been characterized. N	-		
	Methotrexate	Normal risk for m	nethotrexate	toxicity (MTHFR	Normal MTHFR A	ctivity)		INFORMATIV
	Trexall	The patient does not carry the MTHFR 677 T allele, and unless other risk factors are present, the patient is not expected have an increased risk for methotrexate toxicity. Consider using label-recommended dosage and administration.						
	Methylphenidate Ritalin, Aptensio XR, Concerta, Metadate ER, Quillivant ER	The patient's genoty	ype result predi ding to the nee	icts a higher likelih	igh/Normal COMT bod of response to me f the patient. Therapy	ethylphenidat	-	
\	Metoclopramide Reglan				5: Normal Metaboli recommended dosage		tration.	INFORMATIV
	Metoprolol	Normal Sensitivit	y to Metopro	olol (CYP2D6: No	rmal Metabolizer)			ACTIONABL
	Lopressor	Metoprolol can be p requires individual t		andard label-recon	nmended dosage and	administratio	on. Selection of pro	oper dosage
	Mexiletine	Normal Sensitivit	y to Mexileti	ne (CYP2D6: Noi	mal Metabolizer)			ACTIONABL
	Mexitil	Mexiletine can be prescribed at standard label-recommended dosage. A careful titration with ECG recording and monitoring of mexiletine plasma concentrations are recommended until a favorable clinical response is achieved.					-	
	Micafungin	Normal Response	e to Micafung	jin				ACTIONABL
	Mycamine	P450 enzymes. Ever	though micafu vay for micafun	ungin is a substrate	zed by arylsulfatase, c. for and a weak inhibi vivo. No genetically g	tor of CYP3A	in vitro, hydroxyla	
	Milnacipran	Normal Response	e to Milnacip	ran				INFORMATIVE
_	Savella	Pharmacogenetic g in urine. No genetic			y metabolized by UGT			

	Manc	hester	PATIENT INFORMATION NAME: Patient 35962	SPECIMEN DETAILS	ORDERED BY		
	• Unive	rsity	ACC #: 35962 DOB: 1/1/1900 SEX:	COLLECTION DATE: 1/1/19 RECEIVED DATE: 1/1/19 REPORT DATE: 2/8/20	900		
	FOR ACADEMIC PURPOSES ONLY -	NOT FOR CLINICAL USE	JLA.				
V	Mirabegron Myrbetriq	Normal Sensitiv	ity to Mirabegron (CYP2D6:	Normal Metabolizer)	ACTIONABL		
	Tyrbeing	Mirabegron can be	e prescribed at standard label-re	commended dosage and admi	nistration.		
\	Mirtazapine	Normal Sensitiv	ity to Mirtazapine (CYP2D6:	Normal Metabolizer)	ACTIONABL		
	Remeron		e prescribed at standard label-re il a favorable response is achiev	5	nistration. Careful titration is		
\	Nabumetone	Normal Respons	se to Nabumetone		INFORMATIV		
	Relafen	that is further meta (i.e CYP2C9 poor n an altered drug res Guidance: CYP1A2 the therapeutic eff	abolized by CYP2C9 to an inactiv netabolizers) may have higher le sponse. No genetically guided d 2 inhibitors may inhibit the activ	ve metabolite. Theoretically, ind evels of the active metabolite, b rug selection or dosing recomm ation of nabumetone to its acti- nand, CYP1A2 inducers (i.e smol	YP1A2 to an active metabolite (6-MNA) lividuals with reduced CYP2C9 activity ut it is unknown whether this results in nendations are available. Polypharmac ve metabolite resulting in a reduction in king) may result in higher levels of		
	Naltrexone	Good Response	to Naltrexone (OPRM1: Alte	ered OPRM1 Function)	INFORMATIV		
-	Vivitrol, Contrave	good clinical outco more likely to resp	ome with naltrexone therapy. Na ond to this drug. They have a hi	ltrexone-treated patients carryi gher percentage of days abstin	ous genotype that is associated with a ing the OPRM1 118A>G G allele are lent and a lower percentage of heavy ot been reported consistently across		
	Naproxen	Normal Sensitivity to Naproxen INFORM					
	Aleve	Pharmacogenetic guidance: UGT2B7 is responsible for hepatic naproxen acyl glucuronidation, which is the primary elimination pathway for this drug (60% of total clearance). CYP2C9 and CYP1A2 are responsible for the formation of desmethylnaproxen but this pathway is not the primary pathway for the elimination for naproxen. Genetic polymorpl of CYP2C9 has not been found to affect the response to naproxen. No genetically guided drug selection or dosing recommendations are available.					
	Nateglinide	Normal Sensitiv	ity to Nateglinide (SLCO1B1	: Decreased Function)	INFORMATIV		
	Starlix		atient carries one copy of SLCO1B1 rs4149056 C allele, which is associated with intermediate transporter functic linide can be prescribed at label-recommended standard dosage and administration.				
	Nateglinide	Normal Sensitiv	ity to Nateglinide (CYP2C9:	Normal Metabolizer)	INFORMATIV		
	Starlix	The patient's geno dosage and admin		e to nateglinide, and this drug c	an be prescribed at label-recommended		
	Nebivolol	Normal Sensitiv	ity to Nebivolol (CYP2D6: N	ormal Metabolizer)	ACTIONABL		
\checkmark	Bystolic		rescribed at standard label-recc favorable response is achieved.	ommended dosage and adminis	stration. Caution is recommended during		
 	Nefazodone	Normal Sensitiv	ity to Nefazodone (CYP2D6	: Normal Metabolizer)	INFORMATIV		

	7) Monoh	nator	PATIENT INFORMAT	ΓΙΟΝ	SPECIMEN DETAILS	5	ORDERED BY
V	Manch Univer		NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	2	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018	
	FOR ACADEMIC PURPOSES ONLY - NOT						
V	Netupitant- Palonosetron Akynzeo	<u>Netupitant:</u> Netupit derivatives). Metabo guided drug selecti label-recommended	olism is mediated prim	abolized to thi narily by CYP3, endations are tration.	ree major metabolit A4 and to a lesser e: available for this dru	es (desmethyl, xtent by CYP20 ug. Netupitant	N-oxide and a hydroxy-methyl C9 and CYP2D6. No genetically can be prescribed at standard
√	Nortriptyline Pamelor		r y to Nortriptyline (e prescribed at standar				ACTIONABLE
✓	Olmesartan Benicar	Pharmacogenetic gastrointestinal trac	enes is not expected t	n medoxomil is There is virtual	y no further metabo	olism of olmes	ACTIONABLE ive metabolite in the artan. Genetic variability of the edoxomil. No genotype-based
√	Ondansetron Zofran, Zuplenz		e to Ondansetron (ACTIONABLE
√	Oxcarbazepine Trileptal, Oxtellar XR	Pharmacogenetic g be used to identify syndrome, Stevens- by a reductase to its eliminated by direct or dosing recomme	patients at risk for sev Johnson syndrome (S. s active monohydroxy renal excretion, glucu	esults obtaine ere cutaneous JS) and toxic e lated active m uronidation, ar e. Polypharma	adverse reactions s pidermal necrolysis etabolite: 10-hydrox nd hydroxylation (m cy guidance: In the	such as anticor (TEN). Oxcarb kycarbazepine inimal). No ge	INFORMATIVE performed in this patient cannot nvulsant hypersensitivity azepine (prodrug) in converted (MHD). This active metabolite is netically guided drug selection enzyme-inducing drugs, the
✓	Oxybutynin Ditropan	Polypharmacy gui CYP3A4 strong inhi	guidance: no genetica dance: Oxybutynin is	extensively me creases oxybut	etabolized in humar ynin serum concent	s by CYP3A4,	INFORMATIVE dations are available. and coadministration of a fore, use caution when
√	Oxycodone Percocet, Oxycontin		e to Oxycodone (C)		-	administratio	ACTIONABLE
✓	Oxymorphone Opana, Numorphan	No genetically guid CYPs, and genetic v		abolizing enzy	mes are not expected	ed to affect its	INFORMATIVE phone is not metabolized by efficacy or toxicity profiles. ation.

\sum	🕜 Mancl	hester	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY		
	Univer	sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018			
	FOR ACADEMIC PURPOSES ONLY - NO	OT FOR CLINICAL USE					
	Paliperidone Invega		ty to Paliperidone (CYP2D6 e prescribed at standard label-r	: Normal Metabolizer) ecommended dosage and administ	ACTIONABL		
/	Palonosetron Aloxi		e to Palonosetron (CYP2D6		INFORMATIV		
		Palonosetron can b	e prescribed at standard label-	recommended dosage and adminis	stration.		
\	Paroxetine Paxil, Brisdelle	Normal Sensitivity to Paroxetine (CYP2D6: Normal Metabolizer) ACTIONAL Paroxetine can be prescribed at standard label-recommended dosage and administration. Careful titration is recommended until a favorable response is achieved. ACTIONAL					
	Perampanel Fycompa	and CYP3A5. No ge Enzyme-inducing c should be increased Coadministration w	guidance: Perampanel is elimi enetically guided drug selection drugs decrease perampanel pla d when it is added to a stable th ith strong enzyme-inducers ot	5	-inducing antiepileptic drugs. ifampin) should be avoided.		
	Perphenazine Trilafon		ty to Perphenazine (CYP2D be prescribed at standard label-	6: Normal Metabolizer) recommended dosage and admini:	ACTIONABL stration.		
	Phenobarbital	Normal Sensitivi	ty to Phenobarbital (CYP2C	19: Rapid Metabolizer)	INFORMATIV		
	Luminal	CYP2C19 is partly ir	CYP2C19 is partly involved in the metabolism of phenobarbital, and this drug can be prescribed at standard label recommended dosage and administration.				
	Phenytoin Dilantin	The genotype resul		CYP2C9 substrate normal metaboli	ACTIONABL zer. Phenytoin can be prescribed at rum concentrations 7-10 days after		
	Pimavanserin	Normal Respons	e to Pimavanserin		INFORMATIV		
-	Nuplazid	by CYP2J2, CYP2D6 major active metab Polypharmacy gui QT prolongation or (e.g., quinidine, pro (e.g., ziprasidone, c of pimavanserin wit drug is coadministe	, and other CYP and FMO enzy olite (AC-279). There are no av. dance: Pimavanserin prolongs in combination with other dru cainamide) or Class 3 antiarrhy hlorpromazine, thioridazine), ar th CYP3A4 inhibitor increases p	mes. CYP3A4 is the major enzyme r ailable genetically-guided drug sele the QT interval and its use should l gs known to prolong QT interval in thmics (e.g., amiodarone, sotalol), c nd certain antibiotics (e.g., gatifloxa imavanserin exposure and a dose r rs. Coadministration of pimavanse	ection or dosing recommendations. be avoided in patients with known cluding Class 1A antiarrhythmics		

V	FOR ACADEMIC PURPOSES ONLY - 1		NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018				
	Pimozide	Normal Sensitivit	y to Pimozide (CYP2D6: No	ormal Metabolizer)	ACTIONABL			
V	Orap	Pimozide can be pre	escribed at standard label-reco	mmended dosage and administratic increased to a maximum of 10 mg,	on. Starting dose: 1 to 2 mg/day			
√	Piroxicam Feldene		y to Piroxicam (CYP2C9: N escribed at standard label-recc	ormal Metabolizer) mmended dosage and administrati	INFORMATIV			
✓	Posaconazole Noxafil	Pharmacogenetic of and feces account for direct glucuronidation glycoprotein are en- drug selection or do inducers may affect	rmal Response to Posaconazole AC rmacogenetic guidance: Posaconazole is cleared primarily as unchanged drug. The excreted metabolites in feces account for approximately 17% of the administered dose. The metabolic pathways for posaconazole i ct glucuronidation, minor oxidation and dealkylation. CYP3A4 (and possibly CYP1A1 and CYP3A5), UGT1A4, coprotein are enzymes and transporters that play a role in the elimination of this antifungal. No genetically o g selection or dosing recommendations are available. Polypharmacy guidance: UGT and P-glycoprotein in ucers may affect posaconazole plasma concentrations. Concomitant use of posaconazole and these agents s ided unless the benefit to the patient outweighs the risk.					
./	Prasugrel	Normal Response	e to Prasugrel		ACTIONABL			
	Effient	converted to the act Prasugrel active met efficacy or safety pro drug selection or do	tive metabolite primarily by CY tabolite exposure and platelet ofile are also unaffected by CYI	g that is hydrolyzed in the intestine P3A4 and CYP2B6, and to a lesser ex reactivity are not affected by CYP2C P2B6, CYP3A5, and CYP2C9 genetic ailable. Polypharmacy guidance : Pi e P450 enzymes.	xtent by CYP2C9 and CYP2C19. 19 genetic variants. Prasugrel variants. No genetically-guided			
√	Pregabalin Lyrica	Polypharmacy guid Genetic variations in	guidance: No genetically guide dance: Pregabalin is eliminated	ed drug selection or dosing recomm primarily through renal excretion a are not expected to affect its efficacy age and administration.	nd is not metabolized by CYPs.			
	Primidone	Normal Sensitivit	y to Primidone (CYP2C19: I	Rapid Metabolizer)	INFORMATIV			
	Mysoline		partly involved in the metabolism of phenobarbital, the active metabolite of primidone, and this dru t standard label-recommended dosage and administration.					
	Proguanil	Normal Response	e to Proguanil (CYP2C19: R	apid Metabolizer)	INFORMATIV			
	Malarone	Proguanil is metabo increased metabolis	lized to an active metabolite com of proguanil to cycloguanil, guanil can be prescribed at star	cloguanil by CYP2C19. Although th there is insufficient data to whether ndard label-recommended dosage a	such change has a significant			
	Propafenone	Normal Sensitivit	y to Propafenone (CYP2D6	: Normal Metabolizer)	ACTIONABL			
_	Rythmol	•	be prescribed at standard label-recommended dosage and administration. Careful titration is th ECG monitoring until a favorable response is achieved.					
			with co-medications: concurr ficantly increase the plasma co	ent use of propafenone along with (

1	Manc Nanc	hester	PATIENT INFORMATION	SPECIMEN DETAILS		ORDERED BY		
V	Unive	• •	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:		I/1/1900 I/1/1900 2/8/2018			
	FOR ACADEMIC PURPOSES ONLY - I	NOT FOR CLINICAL USE						
	Propranolol	Normal Sensitivit	ty to Propranolol (CYP2D6:	Normal Metabolizer)		ACTIONABL		
	Inderal		prescribed at standard label-re monitoring until a favorable re		administration.	Careful titration is		
V	Protriptyline Vivactil		Normal Sensitivity to Protriptyline (CYP2D6: Normal Metabolizer) Protriptyline can be prescribed at standard label recommended-dosage and administration.					
		Protriptyline can be	prescribed at standard label re	ecommended-dosage and	administration			
	Quetiapine	Normal Response	e to Quetiapine			INFORMATIV		
		metabolite N-desall genetically guided of the clinical response reduced to one sixt itraconazole, indina by 6 fold. Quetiapin treatment (e.g. > 7-	Ind CYP3A5 enzymes may be re- kylquetiapine. However, the cli drug selection or dosing recom e and tolerability of the individ th of original dose when co-n vir, ritonavir, nefazodone). Whe le dose should be increased up 14 days) of a potent CYP3A4 ir nducer is discontinued, the dos	nical significance of these of mendations are available. (ual patient. Polypharmacy nedicated with a potent CY en the CYP3A4 inhibitor is of to 5 fold of the original do nducer (e.g., phenytoin, carl	changes is not Quetiapine do guidance : Qu P3A4 inhibitor discontinued, t ose when used bamazepine, ri	established yet and no se should be titrated based or uetiapine dose should be (e.g., ketoconazole, he dose should be increased in combination with a chronic fampin, St. John's wort etc.).		
√	Rabeprazole Aciphex	-	e to Rabeprazole (CYP2C19 prescribed at standard dosage	-		INFORMATIV		
	Raltegravir	Normal Response	e to Raltegravir			ACTIONABL		
V	Isentress, Dutrebis Pharmacogenetic guidance: Raltegravir is eliminated mainly through metabolism by UGT1A1. Althou metabolizers or patients taking inhibitors of UGT1A1 activity have increased plasma levels of raltegravi are not clinically significant. No dosing adjustments are required for raltegravir in patients who carry guidance: UGT1A1. Polypharmacy guidance: Coadministration of raltegravir with drugs that are strong inducers as rifampin, may result in reduced plasma concentrations of this drug.					1A1. Although UGT1A1 poor		
v		are not clinically sig UGT1A1. Polyphari	nificant. No dosing adjustmen macy guidance: Coadministra	s are required for raltegravition of raltegravitic of raltegrav	vir in patients v	of raltegravir, these changes who carry genetic variants of		
✓ ✓	Ranolazine	are not clinically sig UGT1A1. Polyphar as rifampin, may res	nificant. No dosing adjustmen macy guidance: Coadministra	s are required for raltegravition of raltegravition of raltegravition of raltegravitions of this drug.	vir in patients v	of raltegravir, these changes who carry genetic variants of		
✓ ✓		are not clinically sig UGT1A1. Polypharn as rifampin, may res Normal Sensitivit Ranolazine is metab label-recommended the dose should be	nificant. No dosing adjustmen macy guidance: Coadministra sult in reduced plasma concent	is are required for raltegrav ion of raltegravir with drug rations of this drug. Normal Metabolizer) to a lesser extent by CYP2I he recommended initial do and according to the patie	vir in patients v gs that are stro D6. This drug c gse is 375 mg t	of raltegravir, these changes who carry genetic variants of ing inducers of UGT1A1, such ACTIONABL an be prescribed at standard wice daily. After 2–4 weeks,		
 ✓ 	Ranolazine	are not clinically sig UGT1A1. Polyphar as rifampin, may res Normal Sensitivit Ranolazine is metab label-recommended the dose should be recommended max	nificant. No dosing adjustment macy guidance: Coadministration sult in reduced plasma concent ty to Ranolazine (CYP2D6: polized mainly by CYP3A4, and d dosage and administration. T titrated to 500 mg twice daily, imum dose of 1000 mg twice c es treatment-related adverse e r 375 mg twice daily may be re	is are required for raltegravition of raltegravir with drug rations of this drug. Normal Metabolizer) to a lesser extent by CYP2I he recommended initial do and according to the patie laily. vents (e.g. dizziness, nause	vir in patients v gs that are stro D6. This drug c ose is 375 mg t nt's response, a, vomiting, or	of raltegravir, these changes who carry genetic variants of ing inducers of UGT1A1, such ACTIONABI can be prescribed at standard wice daily. After 2–4 weeks, further titrated to a syncope), down titration of		


	Mancl Univer	hester sity	PATIENT INFORMATION NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900	SPECIMEN DETAILS SPECIMEN TYPE: COLLECTION DATE: 1, RECEIVED DATE: 1,	ORDERED BY /1/1900 /1/1900			
	FOR ACADEMIC PURPOSES ONLY - N	OT FOR CLINICAL USE	SEX:		/8/2018			
/	Repaglinide	Normal Sensitiv	vity to Repaglinide (SLCO1B1	: Decreased Function)	INFORMATIV			
	Prandin, Prandimet	•	s one copy of SLCO1B1 rs414905 be prescribed at label-recommend		ed with intermediate transporter function. dministration.			
/	Risperidone	Normal Sensitiv	vity to Risperidone (CYP2D6:	Normal Metabolizer)	ACTIONABL			
	Risperdal		Risperidone can be prescribed at standard label-recommended dosage and administration. Careful tit recommended until a favorable response is achieved.					
/	Rivaroxaban	Normal Respon	ise to Rivaroxaban		INFORMATIV			
	Xarelto	(ABCB1) and BCRI safety profiles of a strong CYP3A4 in concomitant use o phenytoin, rifamp as combined P-gp increased exposure	Pharmacogenetic guidance: Rivaroxaban is metabolized by CYP3A4, CYP3A5, and CYP2J2. It is also a substrate (ABCB1) and BCRP (ABCG2) transporters. Genetic polymorphisms of these genes are not expected to affect the safety profiles of rivaroxaban. Polypharmacy guidance: Avoid concomitant use of rivaroxaban with combined strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir, and conivapta concomitant use of rivaroxaban with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbama phenytoin, rifampin, and St. John's wort). Patients with renal impairment coadministered rivaroxaban with drugs as combined P-gp and moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, dronedarone, and erythromycin) increased exposure compared with patients with normal renal function and no inhibitor use. Significant increase rivaroxaban exposure may increase bleeding risk.					
1	Rolapitant	Normal Respon	ise to Rolapitant		ACTIONABL			
	Varubi	hydroxylated rola selection or dosin decrease rolapitar moderate CYP2D6 while others shou medication. Rola glycoprotein (P-g	pitant). Rolapitant is eliminated p g recommendations are available nt exposure resulting in a loss of 6 inhibitor and some CYP2D6 sub Id be closely monitored and thei pitant is an inhibitor two major d	primarily through the hepati e. Polypharmacy Guidance efficacy. These drugs should ostrates (e.g. thioridazine, pi r doing adjusted when coac rug efflux transporters: brea	to a major active metabolite, (C4pyrrolidine- ic/biliary route. No genetically guided drug e: Strong CYP3A4 inducers can significantly d be avoided with rolapitant. Rolapitant is a mozide) are contraindicated with rolapitant dministered with this antiemetic ast-cancer-resistance protein (BCRP) and P- ates may result in potential adverse			
/	Rufinamide	Normal Respon	ise to Rufinamide		INFORMATIV			
-	Banzel	 Pharmacogenetic guidance: No genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: Rufinamide is extensively metabolized by carboxylesterases. Cytochrome P450 enzymes and not involved in its metabolism. Therefore, genetic variations in these metabolizing enzymes are not expected to affect efficacy or toxicity profiles. Coadministration of enzyme-inducing antiepileptic drugs produce modest decreases in rufinamide plasma levels, while coadministration of valproate increases the drug levels and requires dose adjustment Patients stabilized on rufinamide should begin valproate therapy at a low dose, and titrate to a clinically effective dose Similarly, patients on valproate should begin rufinamide at a lower dose. 						
/	Sildenafil	Normal Respon	se to Sildenafil		INFORMATIV			
-	Viagra	CYP3A5*3/ [*] 3 gen unknown. Polyph patients taking s	otype compared to those with C harmacy guidance: Sildenafil is r strong CYP3A inhibitors, silden	YP3A5*1/*1 genotype. The onetabolized by CYP3A4 (ma afil exposure is significant	osure is 1.5 times higher in individuals with clinical significance of this change is jor route) and CYP2C9 (minor route). In thy increased, and it is recommended not to f CYP3A may decrease the concentration			

V	Unive	hester rsity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 RECEIVED DATE: 1/1/1900 REPORT DATE: 2/8/2018			
	FOR ACADEMIC PURPOSES ONLY -	NOT FOR CLINICAL USE					
√	Silodosin Rapaflo	metabolites. no ger silodosin is contrai	guidance: silodosin is extensiv netically guided drug selection ndicated with potent CYP3A4 in	ely metabolized by CYP3A4 into pha or dosing recommendations are ava hibitors, as the risk for serious adve cribed with CYP3A4 moderate inhib	ilable. Polypharmacy guidance: rse events is increased at higher		
√	Solifenacin Vesicare	Polypharmacy gui concentrations sign coadministered wi at higher concente	guidance: no genetically guide dance: Coadministration of a C iificantly. Therefore, it is recor ith strong CYP3A4 inhibitors,	ed drug selection or dosing recomm YP3A4 strong inhibitor increases so nmended not to exceed a 5 mg da as the risk for QTc prolongation i f moderate CYP3A4 inhibitors were in hibitors.	lifenacin serum ily dose of solifenacin when nduced by this drug is increased		
✓	Sufentanil Sufenta	Normal Response to Sufentanil INF Pharmacogenetic guidance: No genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: Sufentanil is primarily metabolized by CYP3A4 and so should be used with caution of prescribed with CYP3A4 inhibitors or inducers.					
✓	Sulindac Clinoril	including UGT1A3,	guidance: Sulindac is primarily	eliminated by glucuronidation whic of CYP2C9 in sulindac metabolism is s are available.			
✓	Tacrolimus Prograf	The genotype resul patient may metabo		not express the CYP3A5 protein. Th areful titration of tacrolimus in resp			
✓	Tadalafil Cialis	Polypharmacy gui taking concomitant vardenafil is 10 mg, strong inhibitors of studied, other CYP3 when coadministered	guidance: no genetically guide dance: Tadalafil is extensively i potent inhibitors of CYP3A4, s not to exceed once every 72 h CYP3A4, the maximum recomm BA4 moderate inhibitors would	ed drug selection or dosing recomm netabolized by CYP3A4. Tadalafil f o uch as ketoconazole or ritonavir, the ours. Tadalafil for Once Daily Use nended dose is 2.5 mg. Although sp likely increase tadalafil exposure. Th A4 inducers. This can be anticipated eased efficacy is unknown.	or Use as Needed — For patients maximum recommended dose of — For patients taking concomitant recific interactions have not been e exposure of tadalafil is reduced		
✓	Tamsulosin Flomax	-	e to Tamsulosin (CYP2D6: I prescribed at standard label-re	Normal Metabolizer) commended dosage and administra	ACTIONABL		
✓	Tapentadol Nucynta	and genetic variation	led drug selection or dosing re- ons in these metabolizing enzyr	commendations are available. Taper nes are not expected to affect its eff commended dosage and administra	icacy or toxicity profiles.		

V	Univer	hester sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900	SPECIMEN TYPE: COLLECTION DATE: 1 RECEIVED DATE: 1	/1/1900 /1/1900	
I	FOR ACADEMIC PURPOSES ONLY - N	OT FOR CLINICAL USE	SEX:	REPORT DATE: 2	2/8/2018	
	Telmisartan	Normal Sensitivit	y to Telmisartan		ACTIC	ONABL
-	Micardis	Pharmacogenetic guidance: Telmisartan is metabolized by conjugation to form a pharmacologically inactive acyl glucuronide. Telmisartan is not metabolized by the cytochrome P450 isoenzymes. Genetic variability of the cytochrom P450 genes is not expected to affect the patient's response to telmisartan. No genotype-based dosing adjustments ar available.				
	Terazosin	Normal Response	e to Terazosin		INFORI	ΜΑΤΙν
	Hytrin	Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: The enzymes involved in metabolizing terazosin have not been characterized.				
	Thioridazine	Normal Sensitivity to Thioridazine (CYP2D6: Normal Metabolizer) ACTIONABLE				
	Mellaril	administration.				
	Thiothixene	Normal Response	e to Thiothixene		INFORI	MATIV
-	Navane	Pharmacogenetic guidance: Thiothixene is metabolized by UGTs and by cytochrome P450 enzymes (CYP1A2 and CYP3A4). No genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: It is likely that strong enzyme inducers may lead to substantial decreases in thiothixene plasma concentrations with the potential for reduced effectiveness. Consider increasing the dose of thiothixene when concomitantly used with strong CYP3A4 inducers (e.g., carbamazepine).				
\checkmark	Tiagabine	Normal Response	e to Tiagabine		INFORI	ΜΑΤΙν
	Gabitril	Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: Tiagabine is extensively metabolized by CYP3A4, and therefore this drug should be used with caution when prescribed with CYP3A4 inhibitors. Inducers of CYP3A4 increase tiagabine clearance by 2-fold, and the initial dosage of the drug should be considered carefully when added to a stable therapy regimen containing enzyme-inducing antiepileptic drugs.				
\checkmark	Ticagrelor	Normal Response	e to Ticagrelor		INFORI	MATIV
_	Brilinta	Pharmacogenetic guidance: Ticagrelor is extensively metabolized by CYP3A4 and CYP3A5 to both active and inactive metabolites, and this drug does not require bioactivation to achieve its antiplatelet effect. The drug is also a substrate of P-glycoprotein, encoded by the ABCB1 gene. Studies have shown that the efficacy and safety profile of ticagrelor do not depend on CYP2C19 or CYP3A5 metabolizer statuses. Moreover, preliminary studies indicate that relevant genetic variants within the ABCB1, SLCO1B1, CYP3A4 and UGT2B7 genes do not affect ticagrelor exposure, efficacy or safety profiles. No genetically-guided drug selection or dosing recommendations are available. Polypharmacy guidance: In presence of strong CYP3A4 inhibitors, significantly increased exposure to ticagrelor is expected which may lead to adverse reactions such as dyspnea or bleeding. These drugs should be avoided with ticagrelor. Strong CYP3A4 inducers can significantly decrease ticagrelor exposure (resulting in a loss of efficacy) and these drugs should also be avoided. Ticagrelor is a weak inhibitor of CYP3A4 and P-glycoprotein and some substrates of these proteins should be closely monitored and their dosing adjusted when coadministered with this medication.				
√	Timoptic		ivity to Timolol (CYP2D6: Normal Metabolizer)		ACTIC	ONABL
		Timolol can be prescribed at standard label-recommended dosage and administration.				
√	Tofacitinib	Normal Sensitivity to Tofacitinib (CYP2C19: Rapid Metabolizer)			INFORI	
	Xeljanz		Tofacitinib is metabolized primarily by CYP3A4 with some contribution from CYP2C19. Genetic variations in the CYP2C19 gene do not significantly influence tofacitinib exposure. Tofacitinib can be prescribed according to standard label-recommended dosage and administration (i.e 5 mg twice daily).			

	7) Manal	hester	PATIENT INFORMATION	SPECIMEN DETAILS	0	RDERED BY
V	Univer	rsity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:	1/1/1900 1/1/1900 2/8/2018	
	FOR ACADEMIC PURPOSES ONLY - NO					
	Tolbutamide Orinase		ty to Tolbutamide (CYP2C9			ACTIONABL
	Onnase		e prescribed according to stand levels of glucose/glycosylated		dosage and admin	nistration (dose titration in
√	Tolterodine	Normal Sensitivi	ty to Tolterodine (CYP2D6:	Normal Metabolizer)		INFORMATIV
	Detrol	Tolterodine can be	prescribed at standard label-red	commended dosage and	administration.	
√	Topiramate Topamax	-	e to Topiramate guidance: no genetically guide dance: About 50% of absorbed	-	-	
		is present as metab elimination when th inducing antiepilep titrated slowly, and	olites and conjugates. Topirama ne drug is given as a monothera tic drugs, and may result in redu dose adjustment must be consi e has been associated with hype	ate metabolism by cytoch py. However, this pathwa uced topiramate plasma o idered in presence of indo	nrome P450 enzyn ay is enhanced by concentrations. Th ucers. Concomitar	nes is minor for its concomitant use of enzyme nus, this drug should be nt administration of valproic
	Torsemide	Normal Respons	e to Torsemide (CYP2C9: N	ormal Metabolizer)		INFORMATIV
	Demadex	The patient's genot dosage and admini	ype predicts a normal exposure stration.	to torsemide and this dr	ug can be prescri	bed at label-recommended
	Tramadol	Normal Respons	e to Tramadol (CYP2D6: No	ormal Metabolizer)		ACTIONABL
	Ultram		rescribed at standard label-reco tion is recommended.	mmended dosage and ac	dministration. Indi	vidualization of dose with
\	Trazodone	Normal Respons	e to Trazodone			INFORMATIV
-	Oleptro	This metabolite whi polymorphisms of t selection or dosing to substantial increa with a potent CYP3.	guidance: Trazodone is metabo ich may contribute to adverse e ihis enzyme on the clinical respo recommendations are available ases in trazodone plasma conce A4 inhibitor, the risk of cardiac a inhibit CYP3A4 should be appro	vents, is further metaboli onse to trazodone is not v e. Polypharmacy guidan entrations with the potent arrhythmia may be increa	zed by CYP2D6. T well documented. ce : It is likely that tial for adverse eff	he impact of genetic No genetically guided drug CYP3A4 inhibitors may lead ects. If trazodone is used
	Trifluoperazine	Normal Respons	e to Trifluoperazine			INFORMATIV
-	Stelazine	direct glucuronidati available. Polyphar	guidance: Thrifluoperazine exter ion catalyzed by UGT1A4. No ge macy guidance: It is likely that ma concentrations with the pot	enetically guided drug se strong enzyme inducers	lection or dosing may lead to subs	recommendations are
√	Trospium	Normal Respons	e to Trospium			INFORMATIV

V	Manch Univer	sity	NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:		/1/1900 /1/1900 2/8/2018		
	FOR ACADEMIC PURPOSES ONLY - NO	T FOR CLINICAL USE					
✓	Valbenazine Ingrezza	Valbenazine can be daily which can be in <u>Dose adjustments w</u> coadministered. In p	ncreased after a week of therap	ecommended dosage and a oy to the recommended do daily recommended dose t , the daily recommended d	ACTIONABLE administration. The initial dose is 40 mg once use of 80 mg once daily. to 40 mg if a strong CYP3A4 inhibitor is ose may be reduced based on tolerability.		
	Valproic Acid	Normal Response	e to Valproic acid		INFORMATIV		
-	Depakote, Depakene	 Pharmacogenetic guidance: Genotype results obtained from the pharmacogenetic test performed in this patient car be used to identify patients carrying mutations in mitochondrial DNA polymerase γ (POLG). Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder. Valproic acid is extensively metabolized in the liver, which occurs primarily by glucuronidation with probable contributions of UGT1A6, UGT1A9, and UGT2B7. This drug is also metabolized by a minor CYP–dependent oxidation 					
		pathway, which inclu documenting the im genetically guided c drugs increase valpr	udes multiple enzymes such as apact of genetic polymorphism Irug selection or dosing recom	CYP2A6, CYP2C9, and CYP is of these metabolizing en imendations are available. I higher doses of this drug a	2C19. There are insufficient studies zymes on valproic acid response, and no Polypharmacy guidance: enzyme-inducing re required to maintain therapeutic		
	Valsartan Diovan, Entresto	formation of a mino contribution of CYP2	, guidance: Valsartan is excreted r metabolite, valeryl 4-hydroxy	valsartan, which accounts of valsartan, genetic variabil	ACTIONABLE npound. CYP2C9 is responsible for the for about 9% of a dose. Given the limited ity of the CYP2C9 gene is not expected to nents are available.		
	Vardenafil	Normal Response	e to Vardenafil		ACTIONABL		
	Levitra	Pharmacogenetic g CYP3A5*3/*3 genot Polypharmacy guid inhibitors such as ke patients receiving m should not be exce For itraconazole: 4 24-hour period. Fo	guidance: Preliminary findings ype compared to those with C dance: The dosage of vardenai etoconazole, itraconazole, ritor noderate CYP3A4 inhibitors suc eded in a 72-hour period. Fo 00 mg daily. For clarithromy r ketoconazole: 200 mg daily	YP3A5*1/*1 genotype. The fil may require adjustment i lavir, indinavir, saquinavir, a ch as erythromycin. For ritco or indinavir, saquinavir, at cin: a single dose of 2.5 m y. For itraconazole: 200 m	posure is 3 times higher in individuals with clinical impact of this change is unknown. in patients receiving strong CYP3A4 atazanavir, or clarithromycin, as well as in onavir, a single dose of 2.5 mg vardenafil azanavir, or ketoconazole: 400 mg daily. ng vardenafil should not be exceeded in a ng daily. For erythromycin: a single dose of CYP3A4 may decrease the concentrations of		
	Venlafaxine	Normal Sensitivit	y to Venlafaxine (CYP2D6:	Normal Metabolizer)	ACTIONABL		
	Effexor		orescribed at standard label-re a favorable response is achiev	5	dministration. Careful titration is		
	Vigabatrin	Normal Response	e to Vigabatrin		INFORMATIVE		
•	Sabril	Pharmacogenetic g Polypharmacy guid	guidance: no genetically guide dance: Vigabatrin is eliminatec ariations in these metabolizing	l primarily through renal ex enzymes are not expected	recommendations are available. cretion and is not metabolized by CYPs. I to affect its efficacy or toxicity profiles.		







NAME: Patient 35962

ACC #: 35962

SEX:

DOB: 1/1/1900

SPECIMEN DETAILS

SPECIMEN TYPE: RECEIVED DATE: REPORT DATE:

COLLECTION DATE: 1/1/1900 1/1/1900 2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Test Details

Gene	Genotype	Phenotype	Alleles Tested
CYP2C9	*1/*1	Normal Metabolizer	*2, *3, *4, *5, *6, *11
CYP2C19	*1/*17	Rapid Metabolizer	*2, *3, *4, *4B, *5, *6, *7, *8, *9, *17
CYP2D6	*1/*1	Normal Metabolizer	*2, *3, *4, *4M, *6, *7, *8, *9, *10, *12, *14A, *14B, *17, *29, *35, *41
CYP3A5	*3/*3	Poor Metabolizer	*1D, *2, *3, *3B, *3C, *6, *7, *8, *9
CYP3A4	*1/*1	Normal Metabolizer	*1B, *2, *3, *12, *17, *22
VKORC1	-1639G>A A/A	High Warfarin Sensitivity	-1639G>A
Apolipoprotein E	Indeterminate	Unknown Phenotype	ε2, ε4, (ε3 is reference)
CYP2B6	*1/*1	Normal Metabolizer	*6, *9
CYP1A2	*1F/*1K	Intermediate Metabolizer - Possible Inducibility	*1C, *1D, *1F, *1K, *1L, *1V, *1W
SLCO1B1	521T>C T/C	Decreased Function	521T>C, 388A>G
COMT	Val158Met G/G	High/Normal COMT Activity	Val158Met
OPRM1	A118G A/G	Altered OPRM1 Function	A118G
MTHFR	1298A>C AA 677C>T CC	No Increased Risk of Hyperhomocysteinemia	1298A>C, 677C>T
MTHFR	677C>T CC	Normal MTHFR Activity	1298A>C, 677C>T
Factor II Factor V Leiden	20210G>A GG 1691G>A GG	No Increased Risk of Thrombosis	20210G>A, 1691G>A

Additional Test Results (added to this original report)

HLA-B*15:02	negative/negative	Negative
HLA-B*57:01	negative/negative	Negative
HLA-B*58:01	negative/negative	Negative

Limitation: This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Absence of a detectable gene mutation does not rule out the possibility that a patient has different phenotypes due to the presence of an undetected polymorphism or due to other factors such as drug-drug interactions, comorbidities and lifestyle habits.

Methodology: Array based assays detect listed alleles, including all common and most rare variants with known clinical significance at analytical sensitivity and specificity >99%.

Disclaimer: Manchester University developed the Genotype test. The performance characteristics of this test were determined by Manchester University. It has not been cleared or approved by the U.S. Food and Drug Administration.

Translational Software Disclaimer: The information presented on this report is provided as general educational health information. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Only a physician, pharmacist or other healthcare professional should advise a patient on the use of the medications prescribed.

The pharmacogenetic assay involves use of reporting software and genotype-phenotype associations performed by Translational Software (www.translationalsoftware.com). The software has not been evaluated by the Food and Drug Administration. The software, and the report generated by the software, is not intended to diagnose, treat, cure, or prevent any disease. A qualified designee within the lab uses Translational Software to generate and subsequently review the report. The pharmacogenetic report is one of multiple pieces of information that clinicians should consider in guiding their therapeutic choice for each patient. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to dose guidelines does not necessarily assure a successful medical outcome.





PATIENT INFORMATION

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

APOE Monograph

Clinical Utility

Apolipoproteins (APO) are structural constituents of lipoprotein particles that have critical roles in blood lipid metabolism and transport. Apolipoprotein E (APOE) is a major constituent of triglyceride-rich chylomicrons, very low-density lipoproteins (VLDL), and some subclasses of high-density lipoproteins (HDL). APOE acts as a lipid carrier and transports cholesterol from the cells in the blood vessel wall to the liver for excretion. It also binds to several cell surface receptors to support membrane homeostasis and injury repair in the brain. Defects in APOE can result in hyperlipidemia, which is an important risk factor in the genesis of atherosclerosis and subsequent development of cardiovascular disease (CVD).

Assay Interpretation

There are three common APOE alleles designated ϵ_2 , ϵ_3 , and ϵ_4 , resulting from combinations of the two common variants c.388T>C (rs429358, p.Cys130Arg) and c.526 C>T (rs7412, p.Arg176Cys). These alleles result in E2, E3, and E4 protein isoforms, respectively. The approximate allele frequencies for most populations are 8-12% for ϵ_2 , 74-78% for ϵ_3 , and 14-15% for ϵ_4 .

The reference ranges for both mutations of APOE are c.388T/T and c.526C/C. This is consistent with a ε3/ε3 genotype and a normal APOE function.

Clinical Implications





PATIENT	INFORM	ΙΔΤΙΟΝ

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:
 X

SPECIMEN DETAILS

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

The apolipoprotein E3 is considered the normal isoform and is associated with normal lipid metabolism. The apolipoprotein E2 isoform shows defective binding of remnants to hepatic lipoprotein and delayed clearance from plasma. It is associated with a slower conversion of intermediate-density lipoproteins (IDL) to low-density lipoproteins (LDL), lower cholesterol, and higher triglycerides, compared to the normal apolipoprotein E3 isoform. The apolipoprotein E4 isoform results in the down regulation of the LDL receptor and is associated with increased total cholesterol, triglycerides, and LDL.

1 - Type III Hyperlipoproteinemia

<u>Result Interpretation:</u> APOE genotyping can be used to confirm the diagnosis of suspected type III hyperlipoproteinemia. Patients with symptoms (xanthomas) and with a lipid profile consistent with type III hyperlipidemia are candidates for APOE genotype analysis. Homozygosity for the APOE ϵ^2 allele is strongly associated with type III hyperlipoproteinemia. Over 90% of individuals presenting the clinical type III hyperlipoproteinemia have the rare ϵ^2/ϵ^2 genotype. These individuals have an increased risk of premature vascular disease.

Only 1-5% of individuals with the APOE ϵ^2/ϵ^2 genotype develop type III hyperlipoproteinemia, suggesting that other genetic, hormonal, or environmental factors must contribute the expression of this disease. Despite the accumulation of remnants in the circulation, most (>95%) APOE ϵ^2 homozygous subjects are normolipidemic or even hypolipidemic because of low LDL cholesterol levels. Other non- ϵ^2/ϵ^2 APOE genotypes (ϵ^3/ϵ^3 , ϵ^2/ϵ^3 ϵ^2/ϵ^4 ϵ^3/ϵ^4 ϵ^4/ϵ^4) are not associated with type III hyperlipoproteinemia.

Summary: patients with a lipid profile (tendinous/tuberous xanthomas, elevated cholesterol, triglycerides, very low density lipoprotein (VLDL)) consistent with type III hyperlipoproteinemia are candidates for APOE genotyping. Most patients with type III hyperlipoproteinemia are homozygous for the APOE ϵ 2 allele and homozygosity for ϵ 2 allele is the only genotype associated with type III hyperlipoproteinemia. Factors in addition to the defective receptor binding activity of the apolipoprotein E2 isoform are necessary for manifestation of this disorder and only 1-5% of APOE ϵ 2 homozygous develop type III hyperlipoproteinemia.

2 - Atherosclerotic Cardiovascular Disease

<u>Result Interpretation</u>: genetic testing of APOE genotyping has been proposed for individual cardiovascular risk assessment and/or to predict the response to statin therapy. APOE genotyping can be informative in individuals with premature coronary heart disease or a family history of premature coronary heart disease. The APOE ϵ 4 allele has been linked to pure elevations of low-density lipoproteins (LDL), and the ϵ 4/ ϵ 4 and ϵ 3/ ϵ 4 genotypes are associated with increased serum cholesterol levels.

Although the evidence is not fully consistent, it has been estimated that having the $\epsilon 3/\epsilon 4$ or $\epsilon 4/\epsilon 4$ genotype is associated with on average a 30 -40% increased risk of cardiovascular disease relative to the common $\epsilon 3/\epsilon 3$ genotype.

There is some evidence that having an ϵ^2/ϵ^2 or ϵ^2/ϵ^3 genotype may be associated with a lower CVD risk in Caucasians normolipidemic patients. A proposed explanation of such observation is the association between APOE2 allele and lower Lp(a) concentrations.

Summary: the APOE ϵ 4 allele results in the down regulation of the LDL receptor and is associated with increased total cholesterol, triglycerides, and LDL. Several studies indicate that the ϵ 3/ ϵ 4, ϵ 2/ ϵ 4 or ϵ 4/ ϵ 4 genotypes are associated with increased plasma cholesterol levels. The presence of the ϵ 3/ ϵ 4 or ϵ 4/ ϵ 4 genotype has been suggested as a risk factor for atherosclerosis and coronary heart disease. Thus, the APOE genotype may be useful and informative in individuals with a family history of coronary heart disease as an additional tool for assessing their risk in conjunction with other clinical or laboratory findings. No clinical practice guidelines or position statements from U.S. professional associations were identified that recommended the use of APOE genotyping in cardiovascular risk assessment, including but not limited to the following: the 2013 American College of Cardiology/American Heart Association guidelines for the assessment of cardiovascular risk in asymptomatic patients; the 2009 U.S. Preventive Services Task Force (USPSTF) recommendations on the use of nontraditional risk factors for the assessment of coronary heart disease; the American Diabetes Association and the American College of Cardiology Foundation consensus conference publication.





References

1: Eichner JE et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002 Mar 15;155(6):487-95. 2: Koch W et al. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. Int J Cardiol. 2008 Mar 28;125(1):116-7. 3: Hanis CL et al. Effects of the apolipoprotein E polymorphism on levels of lipids, lipoproteins, and apolipoproteins among Mexican-Americans in Starr County, Texas. Arterioscler Thromb. 1991 Mar-Apr;11(2):362-70. 4: Klos KL et al. Linkage analysis of plasma ApoE in three ethnic groups: multiple genes with context-dependent effects. Ann Hum Genet. 2005 Mar;69(Pt 2):157-67. 5: Bennet AM et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007 Sep 19;298(11):1300-11. 6: Ciftdoğan DY et al. The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery disease. J Clin Lipidol. 2012 Jan-Feb;6(1):81-7. 7: Kofler BM et al. Apolipoprotein E genotype and the cardiovascular disease risk phenotype: impact of sex and adiposity (the FINGEN study). Atherosclerosis. 2012 Apr;221(2):467-70. 8: Carvalho-Wells AL et al. Interactions between age and apoE genotype on fasting and postprandial triglycerides levels. Atherosclerosis. 2010 Oct;212(2):481-7. 9: Sima A et al. Apolipoprotein E polymorphism--a risk factor for metabolic syndrome. Clin Chem Lab Med. 2007;45(9):1149-53. 10: Granér M et al. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis. 2008 May;18 (4):271-7. 11: Utermann G et al. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 1977 Oct 13;269(5629):604-7. 12 : Blum CB. Type III Hyperlipoproteinemia: Still Worth Considering? Prog Cardiovasc Dis. 2016 Sep - Oct;59(2):119-124. 13: Harold D et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009 Oct;41(10):1088-93. 14: Hopkins PN et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler Thromb. 1991 Sep-Oct;11(5):1137-46. 15: Wilson PW et al. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1250-5. 16: Brscic E et al. Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J. 2000 Jun;139(6):979-84. 17: Humphries SE et al. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001 Jul 14:358(9276):115-9. 18; Zhu H et al. The association of apolipoprotein E (APOE) gene polymorphisms with atherosclerosis susceptibility: a metaanalysis. Minerva Cardioangiol. 2016 Feb;64(1):47-54. 19: Song Y et al. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004 Jul 20;141(2):137-47. 20: Xu H et al. Meta-analysis of apolipoprotein E gene polymorphism and susceptibility of myocardial infarction. PLoS One. 2014 Aug 11;9(8):e104608. 21: Schaefer JR. Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly. Eur J Hum Genet. 2009 May;17(5):541-2. 22: Khan TA et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol. 2013 Apr;42(2):475-92. 23: Zhang MD et al. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population: a meta-analysis of 61 studies including 6634 cases and 6393 controls. PLoS One. 2014 Apr 22;9(4):e95463. 24: Cheema AN et al. APOE gene polymorphism and risk of coronary stenosis in Pakistani population. Biomed Res Int. 2015;2015:587465. 25: Zhang Y et al. Meta-analysis for the Association of Apolipoprotein E ε2/ε3/ε4 Polymorphism with Coronary Heart Disease. Chin Med J (Engl). 2015 May 20;128(10):1391-8. 26: Zhao QR et al. Association between apolipoprotein E polymorphisms and premature coronary artery disease: a metaanalysis. Clin Chem Lab Med. 2017 Feb 1;55(2):284-298. 27: Xu M et al. Apolipoprotein E Gene Variants and Risk of Coronary Heart Disease: A Meta-Analysis. Biomed Res Int. 2016;2016:3912175. 28: Moriarty PM et al. Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients. Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):580-588. 29: Mack S et al. A genome-wide association meta-analysis on lipoprotein(a) concentrations adjusted for apolipoprotein(a) isoforms. J Lipid Res. 2017 May 16.



NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900

SPECIMEN DETAILS

COLLECTION DATE: 1/1/1900

1/1/1900

2/8/2018

SPECIMEN TYPE:

RECEIVED DATE:

REPORT DATE:

PATIENT INFORMATION

SEX:



PATIENT INFORMATION

SPECIMEN DETAILS

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

COMT Monograph

Clinical Utility

Catechol-O-Methyltransferase (COMT) is an enzyme responsible for the metabolism of catecholamines and catechol-estrogens in the central nervous system and other organs. Dopamine is cleared mainly by COMT in the frontal cortex, and a reduced activity of this enzyme results in higher synaptic levels of dopamine, which affects prefrontal cortex cognitive response to certain drugs. A single nucleotide polymorphism of the COMT gene produces an amino acid change from valine to methionine (Val158Met) and reduces the enzyme activity by 3- to 4-fold.

Assay Interpretation

The most well studied COMT genetic variant (rs4680; 472G>A) is the one resulting in a valine to methionine change at codon 158. The variant allele called the Met allele is found in 30-47% of Caucasians, 23% of Africans, and 27-32% of Asians. The phenotype is defined by the presence of the reduced activity Met allele (A variant). The wild-type genotype (Val/Val; GG) predicts a high/normal COMT activity, the heterozygous genotype (Val/Met; GA) predicts an intermediate COMT activity, and the homozygous (Met/Met; AA) results in a low COMT activity.

The reference range for COMT metabolic status is COMT Val158Met GG (Val/Val) (wild-type), which is consistent with a high/normal COMT activity.

Clinical Implications

Several complex associations with the Val158Met variant as a risk factor for numerous diseases have been found, but seem to have limited predictive value. The response to some psychotropic medications seems to be dependent to some extent upon the COMT status. In general, the wild-type genotype result predicts a good response to methylphenidate and amphetamines in the treatment of attention deficit hyperactivity disorder. In the treatment of pain, patients who are homozygous for the Met allele require lower doses of morphine to achieve analgesia.

References

1: De Gregori et al. Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur J Clin Pharmacol. 2013 May 19. 2 : Hamidovic et al. Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr Genet. 2010 Jun;20(3):85-92. 3 : Blasi et al. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci. 2005 May 18;25(20):5038-45. 4 : Mattay et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6186-91.





PATIENT INFORMATION

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

CYP1A2 Monograph

Clinical Utility

The cytochrome P450 1A2 (CYP1A2) accounts for 13% of total CYP in the human liver, and is responsible for metabolizing 8-10% of commonly used drugs as well as natural compounds such as caffeine. A large inter-individual variability in the elimination of drugs that are metabolized by CYP1A2 has been observed, which has been ascribed to genetic variations and environmental factors. CYP1A2 activity is highly inducible (increased) by environmental factors including smoking (tobacco), some drugs, and several dietary compounds (cruciferous vegetables).

Assay Interpretation

More than 20 different alleles have been characterized for the CYP1A2 gene, and some have been shown to affect enzyme activity and its sensitivity towards inducers (inducibility). The CYP1A2*1F is the most studied allele and results in a rapid metabolizer phenotype in the presence of inducers, while CYP1A2*1K and *1C alleles result in enzymes that are less active and less sensitive to induction. The CYP1A2*1F allele is found in 25-50% of Caucasians, 30% of Asians, and 50% of Ethiopians. The genotype-phenotype relationship for CYP1A2 is not well established, and can be expressed in terms of metabolic capacity as well as sensitivity towards induction (inducibility). Individuals are predicted to have CYP1A2 normal, intermediate, or poor metabolic capacity, with high, possible, or low inducibility depending on their genotype.

The reference range for CYP1A2 metabolic status is CYP1A2 *1A/ *1A, which is consistent with a normal metabolizer that is possibly inducible.

Clinical Implications

CYP1A2 genotype can help identify patients with high or low sensitivity to inducing agents, especially those released during smoking. **The clinical relevance of this sensitivity becomes important in patients who are smokers or who quit smoking.** Patients with the highly inducible genotype CYP1A2*1F/*1F can experience loss of response to drug substrates while they are exposed to dietary or environmental inducers, and therefore may require higher doses.

The following drugs used in the management of pain and various psychiatric conditions are metabolized extensively by CYP1A2 and are sensitive to its function: clozapine (Clozaril), duloxetine (Cymbalta), olanzapine (Zyprexa), and tizanidine (Zanaflex). CYP1A2 also metabolizes other important drugs such as melatonin, ondansetron (Zofran), pomalidomide (Pomalyst), ramelteon (Rozerem), ropivacaine (Naropin), and tasimelteon (Hetlioz).

CYP1A2 metabolism is highly sensitive to inhibition and induction, and the occurrence of drug-drug interactions can have profound effects on the pharmacokinetics, response, and safety profiles of many CYP1A2 drug substrates.

Inhibitors

Some known strong CYP1A2 inhibitors include: ciprofloxacin (Cipro), enoxacin (Penetrex), fluvoxamine (Luvox) and zafirlukast (Accolate).

Some known **moderate to weak** CYP1A2 inhibitors include: allopurinol (Zyloprim), mexiletine (Mexitil), norfloxacin (Norflox), peginterferon alfa-2a (Pegasys), obeticholic acid (Ocaliva), oral contraceptives, ticlopidine (Ticlid), vemurafenib (Zelboraf) and zileuton (Zyflo).

Inducers

Known CYP1A2 inducers include: carbamazepine (Tegretol), montelukast (Singulair), moricizine (Ethmozine), omeprazole (Prilosec), phenobarbital, phenytoin (Dilantin), primidone (Mysoline) and rifampin (Rifadin).

Some dietary and environmental compounds found in charcoal-grilled food, cigarette smoke and cruciferous vegetables can also increase CYP1A2 activity.

References

1: Metabolic Drug Interactions. RH Levy, KE Thummel, WF Trager. Publisher: Lippincott Williams & Wilkins (March 15, 2000). 2: Zhou et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89-295 3 : Thorn et al. PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics. 2012 Jan;22(1):73-7. 4 : Aklillu et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003 Sep;64(3):659-69. 5 : Zhou et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010 May;42(2):268 -354.





PATIENT INFORMATION

NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 **RECEIVED DATE:** 1/1/1900 REPORT DATE: 2/8/2018

CYP2B6 Monograph

Clinical Utility

The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of 4% of clinically important medications. This enzyme is highly polymorphic: to date, 37 different variants have been identified. The CYP2B6 assay identifies some common variants that are associated with variability in enzyme activity.

Assay Interpretation

CYP2B6 enzyme activity defines a normal or an abnormal (intermediate or poor) metabolizer status for a given individual. Several variant alleles have been identified and result in different CYP2B6 isoforms that functionally are fully active, partially active, inactive, or have increased activity. The CYP2B6*1 allele is considered wild-type and encodes a functionally active enzyme (normal). The alleles *6, *7, *9, *11, *16, *18, and *36 encode a decreased activity enzyme. The *22 alleles represents a gain-of-function allele. The functional impact of variants that define the CYP2B6 *4 and *5 alleles is drug dependent.

The most common functionally deficient allele is CYP2B6*6. It is found in 7-18%, 10-17%, 23%, and 33% of Caucasians, Asians, Mexican-Americans, and African-Americans, respectively. CYP2B6 *18 is found only in individuals of African descent, with a frequency of 4-7%.

The genotype-phenotype relationship is not well established, and there is a lack of consistency regarding the clinical impact of certain allelic variants. The following provisional genotype-to-phenotype assignment can be used: individuals with two fully active alleles are considered normal (extensive) metabolizers. Individuals with one fully active allele with either a partially active or an inactive allele are considered intermediate metabolizers. Individuals with two partially active alleles or two inactive alleles are considered poor metabolizers. Individuals carrying two increased function alleles or one active allele with a gain-of-function allele are classified as normal/rapid metabolizers.

The reference range for CYP2B6 metabolic status is CYP2B6 *1/ *1, which is consistent with a normal metabolizer.

Clinical Implications

CYP2B6 plays a role in the metabolism of the following drugs: artemisinin, bupropion (Wellbutrin), cyclophosphamide (Cytoxan), efavirenz (Sustiva), ketamine (Ketalar), meperidine (Demerol), methadone (Dolophine), nevirapine (Viramune), propofol (Diprivan), and selegiline (Eldepryl).

The impact of CYP2B*6 polymorphism on the pharmacokinetics and the clinical response have been studied in patients taking methadone, bupropion, and efavirenz. Limited evidence exists regarding the clinical impact of other polymorphisms.

Inhibitors or inducers of the CYP2B6 enzyme may modify its activity and change the patient's metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2B6 inhibitors or inducers.

Inhibitors

Some known CYP2B6 inhibitors include: clopidogrel (Plavix), darunavir (Prezista), prasugrel (Effient), ritonavir (Norvir), thiotepa (Tepadina), ticlopidine (Ticlid) and voriconazole (Vfend).

Inducers

Some CYP2B6 inducers include: artemether (Coartem), carbamazepine (Tegretol), dabrafenib (Tafinlar), efavirenz (Sustiva), metamizole, nevirapine (Viramune), phenobarbital, phenytoin (Dilantin), rifampin (Rimactane), ritonavir (Norvir) and St. John's wort.

References

1: CYP2B6 Allele Nomenclature: www.cypallele.ki.se/cyp2b6.htm 2: Li et al. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics. 2012 Apr;13(5):555-70. 3: Li et al. The CYP2B6*6 Allele Significantly Alters the N-Demethylation of Ketamine Enantiomers In Vitro. Drug Metab Dispos. 2013 Jun;41(6):1264-72. 4: Zanger and Klein. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24. 5: Zanger et al. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007 Jul;8(7):743-59. 6: Zhu et al. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther. 2012 Dec;92(6):771-7. 7: Benowitz et al. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics. 2013 Mar;23(3):135-41.





PATIENT INFORMATION

SPECIMEN DETAILS

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

CYP2C19 Monograph

Clinical Utility

The cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of 10% of clinically important medications. This enzyme is highly polymorphic and more than 30 different alleles have been identified in various ethnicities. The CYP2C19 assay identifies common and rare variants that are associated with variability in CYP2C19 enzyme, which has important pharmacological and toxicological implications for antidepressants, benzodiazepines, antiplatelets, and proton-pump inhibitors.

Assay Interpretation

CYP2C19 enzyme activity defines a normal or abnormal (intermediate, poor, rapid or ultra-rapid) metabolizer status for a given individual. Several variant alleles have been identified and result in different isoforms of the CYP2C19 enzyme that functionally exhibit normal function, reduction function, no function or increased function. The CYP2C19*1 allele is considered wild-type/reference allele and encodes a functionally active enzyme (normal function allele). The alleles *2, *3 *4, *5, *6, and *8 encode an inactive enzyme and are referred to as no function alleles while the *9 and *10 alleles are classified as reduced function alleles. The CYP2C19*17 is an increased function allele.

The CYP2C19 genotype-phenotype relationship is established based on the allele's function. An Individual with two normal function alleles is considered a normal metabolizer while an individual carrying two no function alleles is considered a poor metabolizer. An individual carrying one normal function allele with one no function allele or one no function allele with one increased function allele is classified as an intermediate metabolizer. Individuals with two increased function alleles are considered ultra-rapid metabolizers and carriers of one increased function allele with one normal function allele are referred to as rapid metabolizers. Because of limited evidence, individuals carrying two decreased function alleles OR those carrying one normal or increased function allele with one decreased function allele are provisionally categorized as intermediate metabolizers.

Clinical Implications

There is substantial evidence linking the CYP2C19 polymorphisms to variability in the pharmacological and safety profiles of the following therapies used in psychiatric conditions and pain management: amitriptyline (Elavil), sertraline (Zoloft), clobazam (Onfi), citalopram (Celexa), escitalopram (Lexapro), diazepam (Valium), imipramine (Tofranil), and carisoprodol (Soma). CYP2C19 plays a minor role in the elimination of methadone (Dolophine).

Cardiovascular medications that are metabolized by CYP2C19 include the prodrug clopidogrel (Plavix), propranolol (Inderal), and cilostazol (Pletal). Proton-pump inhibitors such as omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid), dexlansoprazole (Dexilant), and pantoprazole (Protonix) are major substrates of CYP2C19.

Brivaracetam (Briviact) is primarily metabolized by hydrolysis and by hydroxylation. The hydrolysis reaction is mediated by amidase and the hydroxylation is mediated by CYP2C19. Brivaracetam exposure is increased by 22% and 42%, in CYP2C19 intermediate and poor metabolizers, respectively. CYP2C19 poor metabolizers and patients using inhibitors of CYP2C19 may therefore require dose reduction to avoid concentration-dependent toxicity.

CYP2C19 is significantly involved in the metabolism of voriconazole (Vfend) and the disposition of this antifungal is affected by CYP2C19 genetic polymorphisms. The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers.

Inhibitors or inducers of CYP2C19 enzyme may modify its activity and change the patient's metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2C19 inhibitors or inducers.


Inhibitors

Some known CYP2C19 inhibitors include: armodafinil (Nuvigil), delavirdine (Rescriptor), esomeprazole (Nexium), etravirine (Intelence), felbamate (Felbatol), fluconazole (Diflucan), fluoxetine (Prozac), fluvoxamine (Luvox), moclobemide (Manerix), modafinil (Provigil), omeprazole (Prilosec), oxcarbazepine (Trileptal), ticlopidine (Ticlid), topiramate (Topamax) and voriconazole (Vfend).

Inducers

Some known CYP2C19 inducers include: artemether (Coartem), carbamazepine (Tegretol), efavirenz (Sustiva), enzalutamide (Xtandi), fosphenytoin (Cerebyx), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin) and St. John's wort.





References

1: Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2: Metabolism and elimination. J Psychiatr Pract. 2012 Sep;18(5):361-8. 2: Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: part 1. J Psychiatr Pract. 2012 May;18(3):199-204. 3: Hicks et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin Pharmacol Ther. 2013 Jan 16 4: Swen et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662-73. 5: Wilffert et al. KNMP working group Pharmacogenetics. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm. 2011 Feb;33(1):3-9. 6: Psychiatric Pharmacogenomics. David A. Mrazek. Publisher: Oxford University Press, USA; 1 edition (May 28, 2010) 7: Briviact Prescribing Label (label approved on 02/18/2016). 8: Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ. Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16.





PATIENT INFORMATION

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

CYP2C9 Monograph

Clinical Utility

The cytochrome P450 2C9 (CYP2C9) is involved in the metabolism of 15% of clinically important medications. This enzyme is highly polymorphic: to date, 30 variants have been identified. The CYP2C9 assay identifies some common variants that are associated with variability in CYP2C9 enzyme activity, which has important pharmacological and toxicological implications for anticonvulsants, anticoagulants, and certain antidiabetics.

Assay Interpretation

CYP2C9 enzyme activity defines a normal or abnormal (intermediate and poor) metabolizer status for a given individual. Several variant alleles have been identified and result in different CYP2C9 isoforms that functionally are fully active, partially active, or inactive. The CYP2C9*1 allele is considered wild-type and encodes a functionally active enzyme (normal). The alleles *2, *3, *4, *5, and *11 encode a partially active enzyme. The allele *6 is a null allele encoding for an inactive enzyme.

The genotype-phenotype relationship is established based on the allele's activity. Individuals with two fully active alleles are considered normal (extensive) metabolizers. Individuals with one fully active allele with either a partially active or an inactive allele are considered intermediate metabolizers. Individuals with two partially active alleles or with two inactive alleles are considered poor metabolizers.

The reference range for CYP2C9 metabolic status is CYP2C9 *1/*1, which is consistent with a normal metabolizer.

Clinical Implications

Abnormal CYP2C9 activity affects the therapeutic outcome of a variety of drugs used to treat cardiovascular and other conditions. Following the administration of drug substrates, the clinical manifestation in a poor or an intermediate metabolizer depends on the characteristics of the drug (i.e., the amount of drug/metabolites that is cleared by the enzyme), and the safety and pharmacological profiles of the drug and its metabolites. Within the medications used to treat cardiovascular conditions, there is compelling evidence that the response to certain angiotensin II inhibitors, statins, and anticoagulants is altered in individuals exhibiting abnormal CYP2C9 activity.

CYP2C9 plays a role in the metabolism of the following psychotropic drugs: fluoxetine (Prozac), phenytoin (Dilantin), and primidone (Mysoline). Several NSAIDs and Cox-2 inhibitors are substrates of CYP2C9, and patients with reduced CYP2C9 activity may have higher plasma levels of celecoxib (Celebrex), flurbiprofen (Ocufen), piroxicam (Feldene), or meloxicam (Mobic). CYP2C9 plays a minor role in the elimination of diclofenac (Voltaren), sulindac (Clinoril), and naproxen (Aleve).

Cardiovascular medications that are metabolized by CYP2C9 include warfarin (Coumadin), fluvastatin (Lescol), losartan (Cozaar), and irbesartan (Avapro).

Other important drugs metabolized by CYP2C9 include antidiabetics such as tolbutamide, glibenclamide (Micronase), glipizide (Glucotrol), and nateglinide (Starlix).

Inhibitors or inducers of the CYP2C9 enzyme may modify its activity and change the patient's metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2C9 inhibitors or inducers.

Inhibitors

Some known CYP2C9 inhibitors include: amiodarone (Cordarone), capecitabine (Xeloda), chloramphenicol, cimetidine (Tagamet), co-trimoxazole (Septra), danazol (Danocrine), delavirdine (Rescriptor), disulfiram (Antabuse), efavirenz (Sustiva), etravirine (Intelence), fluconazole (Diflucan), 5-fluorouracil (Adrucil), fluoxetine (Prozac), fluvastatin (Lescol), fluvoxamine (Luvox), gemfibrozil (Lopid), lomitapide (Juxtapid), metronidazole (Flagyl), miconazole (Oravig), oxandrolone (Oxandrin), phenytoin (Dilantin), sulfamethoxazole (Bactrim), sulfinpyrazone (Anturane), tamoxifen (Nolvadex), tigecycline (Tygacil), toremifene (Fareston), voriconazole (Vfend) and zafirlukast (Accolate).

Inducers

Some known CYP2C9 inducers include: aprepitant (Emend), bosentan (Tracleer), carbamazepine (Tegretol), dabrafenib (Tafinlar), elvitegravir (Genvoya, Stribild), enzalutamide (Xtandi), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin, Rimactane), rifapentine (Priftin), ritonavir (Norvir) and St. John's wort.





NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:

PATIENT INFORMATION

SPECIMEN DETAILS

SPECIMEN TYPE:	
COLLECTION DATE:	1/1/1900
RECEIVED DATE:	1/1/1900
REPORT DATE:	2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

References

Swen et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662-73. 2: Wilffert et al. KNMP working group Pharmacogenetics. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm. 2011 Feb;33(1):3-9. 3: Wang et al. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab. 2009 Sep;10(7):781-834. 4- Wyatt et al. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. Pharmacogenomics J. 2012 Dec;12(6):462-7





NAME: Patient 35962

1/1/1900

ACC #: 35962

DOB:

SEX:

ON SPECIMEN DETAILS

RECEIVED DATE:

REPORT DATE:

SPECIMEN TYPE: COLLECTION DATE: 1/1/1900

1/1/1900

2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

CYP2D6 Monograph

Clinical Utility

The cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of 25% of clinically important medications. This enzyme is highly polymorphic: more than 100 different variants have been identified. The CYP2D6 assay identifies common variants that are associated with variability in CYP2D6 enzyme activity, which has important pharmacological and toxicological implications for antidepressants, antipsychotics, opioids, beta-blockers, and antiarrhythmics.

Assay Interpretation

CYP2D6 enzyme activity defines a normal or abnormal (intermediate, poor, or ultra-rapid) metabolizer status for a given individual. Commonly tested CYP2D6 variant alleles are classified into functional groups: Full or normal function (e.g., CYP2D6 *1, *2 and *35), reduced function (e.g., CYP2D6*9, *10, *14B, *17, *29, and *41) and no function (e.g., CYP2D6 *3, *4, *5, *6, *7, *8, *11, *12, *14A, *15, *36 and *56). Increased CYP2D6 activity is found in individuals carrying multiple copies of functional alleles. CYP2D6 is subject to gene duplications, and these are denoted "XN", where N represents the number of CYP2D6 gene copies when available.

The genotype-phenotype relationship is established using a scoring system that assigns an activity value to every CYP2D6 allele, in order to assign a predicted phenotype. For a given genotype, the activity values of the constituent alleles are added together to calculate the CYP2D6 activity score. This activity score (AS) is then used to assign a predicted phenotype as follows: AS of 0 predicts a poor metabolizer, AS ranging between 1 and 2 predicts a normal (extensive) metabolizer, AS=0.5 predicts an intermediate metabolizer, and AS greater than 2 predicts an ultra-rapid metabolizer. Fully functional alleles are assigned an activity value of 1, reduced function alleles have an activity value of 0.5, while non-functional alleles are assigned an activity value of 0.

The reference range for CYP2D6 metabolic status is a CYP2D6 *1/ *1 genotype, which is consistent with a normal metabolizer.

Clinical Implications





 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

SPECIMEN DETAILS

ORDERED BY

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

There is substantial evidence linking the CYP2D6 polymorphisms to variability in the pharmacological and safety profiles of the following psychotropics: desipramine (Norpramin), imipramine (Tofranil), amitriptyline (Elavil), nortriptyline (Pamelor), haloperidol (Haldol), trimipramine (Surmontil), venlafaxine (Effexor), doxepin (Silenor), aripiprazole (Abilify), atomoxetine (Strattera), duloxetine (Cymbalta), risperidone (Risperdal), clomipramine (Anafranil), and pimozide (Orap).

CYP2D6 polymorphisms have been shown to affect the pharmacological and safety profiles of the following analgesics: codeine, tramadol (Ultram), and hydrocodone (Vicodin). Codeine and tramadol are prodrugs that need to be activated by CYP2D6. Poor metabolizers are at high risk of therapy failure when given codeine or tramadol. On the other hand, ultra-rapid metabolizers may experience increased toxicity when given standard dosage of codeine or tramadol. Because CYP3A4 is also involved in the metabolism of oxycodone, patients with abnormal CYP2D6 activity may still experience adequate analgesia when taking this drug. CYP2D6 polymorphism has been shown to affect dihydrocodeine (Synalgos-DC) pharmacokinetics and can potentially alter the response to this drug.

Morphine, oxymorphone (Opana), hydromorphone (Dilaudid), butorphanol (Stadol), fentanyl (Duragesic), buprenorphine (Butrans), methadone (Dolophine), morphine (Avinza), and tapentadol (Nucynta) are not substrates of CYP2D6, and the patient's response to these drugs is not expected to be affected by polymorphisms in this enzyme.

Several important cardiovascular medications are metabolized by CYP2D6, and include: metoprolol (Lopressor), carvedilol (Coreg), flecainide (Tambocor), and propafenone (Rythmol).

Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor used for the long-term treatment of adult patients with Gaucher disease type 1. Both the FDA-approved drug label and the EMA Summary of Product Characteristics for this drug state that CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of eliglustat to achieve a therapeutic effect. Therefore this drug should not be used in these individuals. Patients who are CYP2D6 intermediate and normal metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily.

Cevimeline (Evoxac) is a muscarinic agonist indicated for the treatment of symptoms of dry mouth in patients with Sjögrens Syndrome. Both CYP2D6 and CYP3A are responsible for the metabolism of cevimeline, and this drug should be used with caution in individuals who are CYP2D6 poor metabolizers, as they may be at a higher risk of adverse events.

Inhibitors of the CYP2D6 enzyme may modify its activity and change the patient's metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2D6 inhibitors. Although there are no known clinical inducers of CYP2D6, the pharmacokinetics of a drug substrate can be affected by inducers of other enzymes (such as CYP3A) that are involved in the metabolism of that drug.

Inhibitors

Some known **strong and moderate** CYP2D6 inhibitors include: abiraterone (Zytiga), bupropion (wellbutrin), cinacalcet (Sensipar), cobicistat (Stribild), duloxetine (Cymbalta), ecstasy, fluoxetine (Prozac), paroxetine (Paxil), quinidine (Quinidex), rolapitant (Varubi), terbinafine (Lamisil), mirabegron (Myrbetriq), panobinostat (Farydak), peginterferon alfa-2b (Sylatron) and tipranavir/ritonavir (Aptivus).

Some known **weak** CYP2D6 inhibitors include: amiodarone (Cordarone), celecoxib (Celebrex), clobazam (Onfi), desvenlafaxine (Pristiq), diltiazem (Cardiazem), diphenhydramine (Benadryl), Echinacea, escitalopram (Lexapro), febuxostat (Uloric), gefitinib (Iressa), hydralazine (Apresoline), hydroxychloroquine (Plaquenil), imatinib (Gleevec), lorcaserin (Belviq), methadone (Dolophine), perphenazine (Trilafon), propafenone (Rythmol), ranitidine (Zantac), ritonavir (Norvir), sertraline (Zoloft), telithromycin (Ketek), venlafaxine (Effexor) and verapamil (Isoptin, Covera-HS).

References

1- Swen et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662-73. 2: Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. 3: Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. 4: Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2. Metabolism and elimination. J Psychiatr Pract. 2012 Sep;18(5):361-8. 5: Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: part 1. J Psychiatr Pract. 2012 Sep;18(5):361-8. 6: D'Empaire et al. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? J Psychiatr Pract. 2011 Sep;17(5):330-9. 7: Hicks et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin Pharmacol Ther. 2013 Jan 16. 8: Gaedigk et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb;83(2):234-42. 9- Crews et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2DE Exp(12):321-6. 10- Meyer et al. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011Feb;12(2):215-3. 11-Evoxac FDA Prescribing Label. 12-Cerdelga FDA Prescribing Label.





PATIENT INFORMATION

NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:

SPECIMEN TYPE: **RECEIVED DATE:**

COLLECTION DATE: 1/1/1900 1/1/1900 REPORT DATE: 2/8/2018

CYP3A4 Monograph

Clinical Utility

The cytochrome P450 3A4 and 3A5 (CYP3A4 and CYP3A5) account for 40-80% of total CYP in human liver and intestine, respectively. Most importantly, CYP3A enzymes metabolize 50% of commonly used drugs. CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity, and the contribution of CYP3A5 in the overall metabolism is smaller than the one for CYP3A4. The overall CYP3A metabolism status is expected to affect drugs that have a narrow therapeutic index.

Assay Interpretation

A limited number of variants identified within the CYP3A4 and CYP3A5 genes have been associated with significant alterations in enzyme activity and subsequent variability in therapeutic response. For CYP3A5, individuals with the less prevalent "normal metabolizer phenotype" may metabolize drugs faster than those with the more common "poor metabolizer phenotype". This may result in increased toxicity or loss of efficacy.

The CYP3A4*1B variant is the most studied, and results in an enzyme with a moderately decreased activity. It occurs in 50% of African-Americans, 3-5% of Caucasians, and <1% of Asians. The CYP3A4*2, *3, *12, and *17 are also considered decreased activity alleles. Recently, the CYP3A4 *22 allele has been characterized as a decreased function allele that can be clinically relevant (associated with a decreased clearance of certain substrates). The genotype-phenotype relationship for CYP3A4 is not well established, and individuals are predicted to have a CYP3A4 normal or intermediate metabolic capacity.

The reference range for CYP3A4 metabolic status is CYP3A4 *1/ *1, which is consistent with a normal metabolizer.

The variant results in an enzyme with no activity, and is the most common variant in the general population. This variant is found on all the CYP3A5*3 alleles. The CYP3A5 *6 and *7 are also no function alleles. The functional effects of the CYP3A5 alleles *2, *4, *5 *8, and *9 are not well established. The CYP3A5 *1 functional allele produces an active enzyme, and is found in 5% of Caucasians, 20% of Asians, and 15-50% of Africans. Individuals with two CYP3A5 no function alleles are classified as poor metabolizers while those carrying one copy of a functional CYP3A5*1 allele are considered intermediate metabolizers. A subject carrying two copies of the functional CYP3A5*1 allele is considered a normal metabolizer. CYP3A5 poor metabolizers represent 50% of Asians and 90% of Caucasians.

The reference range for CYP3A5 metabolic status is CYP3A5 *1/*1, which is consistent with a normal metabolizer. This genotype is the least prevalent in Caucasians and Asians.

Clinical Implications

CYP3A4 and CYP3A5 genotypes can help identify patients with high or low overall CYP3A activity. Although these two enzymes metabolize many drugs, the response of only a few (such as narrow therapeutic index drugs) is expected to change significantly by genetic polymorphisms. Fentanyl (Duragesic) is a narrow therapeutic drug that is mainly metabolized by CYP3A. There is limited evidence suggesting that the response to this drug is altered in individuals with abnormal CYP3A activity.

The following drugs used in pain management and various psychiatric conditions are metabolized extensively by CYP3A: fentanyl (Duragesic), oxycodone (Oxycontin), buprenorphine (Suboxone), carbamazepine (Tegretol), quetiapine (Seroquel), ziprasidone (Geodon), alprazolam (Xanax), midazolam (Versed), triazolam (Halcion), nefazodone (Serzone), trazodone (Oleptro), vilazodone (Vibryd), zaleplon (Sonata), and zolpidem (Ambien). CYP3A contributes to a small extent in the elimination of methadone (Dolophine).

Within the major therapeutic classes used in cardiovascular conditions, the following drugs are substantially metabolized by CYP3A: atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), nifedipine (Procardia), verapamil (Verelan), nicardipine (Cardene), felodipine (Plendil), nisoldipine (Sular), clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta), cilostazol (Pletal), amiodarone (Cordarone), quinidine (Qualaquin), disopyramide (Norpace), losartan (Cozaar), rivaroxaban (Xarelto), and apixaban (Eliquis).

CYP3A metabolism is highly sensitive to inhibition and induction when a patient is taking multiple drugs. In this case, occurrence of drug-drug interactions can have profound effects on the pharmacokinetics, as well as the responses and safety profiles of many CYP3A drug substrates.





 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:
 Content of the second se

SPECIMEN DETAILS

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Inhibitors

Some known **strong** CYP3A inhibitors include: boceprevir (Victrelis), clarithromycin (Biaxin), clofazimine (Lamprene), conivaptan (Vaprisol), grapefruit juice (high dose), idelalisib (Zydelig), itraconazole (Sporanox), ketoconazole (Nizoral), lopinavir, (Kaletra), nefazodone (Serzone), nelfinavir (Viracept), paritaprevir (Technivie), posaconazole (Noxafil), ribociclib (Kisqali), ritonavir (Norvir), saquinavir (Invirase), telaprevir (Incivek), telithromycin (Ketek), tipranavir (aptivus), troleandomycin (TAO) and voriconazole (Vfend).

Some known **moderate** CYP3A inhibitors include: amprenavir (agenerase), aprepitant (Emend), atazanavir (Reyataz), ciprofloxacin (Cipro), darunavir (Prezista), diltiazem (cardizem), erythromycin (Eryc), fosamprenavir (Lexiva), fluconazole (Diflucan), grapefruit juice (low dose), imatinib (Gleevec), quinupristin/dalfopristin (Synercid) and verapamil (Isoptin, Covera-HS).

Some known **weak** CYP3A inhibitors include: amiodarone (Cordarone), amlodipine (Norvasc), atorvastatin (Lipitor), bicalutamide (Casodex), cilostazol (Pletal), cimetidine (Tagamet), fluoxetine (Prozac), fluoxamine (Luvox), ranitidine (Zantac), ranolazine (Ranexa), sertraline (Zoloft) and ticagrelor (Brilinta).

Inducers

Some known **strong** CYP3A inducers include: carbamazepine (Tegretol), enzalutamide (Xtandi), fosphenytoin (Cerebyx), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin), rifapentine (Priftin) and St. John's wort.

Some known **moderate** CYP3A inducers include: artemether (Coartem), bosentan (Tracleer), dabrafenib (Tafinlar), efavirenz (Sustiva), etravirine (Intelence), modafinil (Provigil), nafcillin (Unipen), nevirapine (Viramune) and rifabutin (Mycobutin).

Some known **weak** CYP3A inducers include: aprepitant (Emend), clobazam (Onfi), dexamethasone (Decadron), Echinacea, fosamprenavir (Lexiva), lesinurad (Zurampic), methylprednisolone (Medrol), midostaurin (Rydapt), oxcarbazepine (Trileptal), pioglitazone (Actos) and rufinamide (Banzel).

References

1- Metabolic Drug Interactions. RH Levy, KE Thummel, WF Trager. Publisher: Lippincott Williams & Wilkins (March 15, 2000). 2: Zhou et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89-295 3- Isoherranen et al. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos. 2008 Jan;36(1):146-54. 4- Williams et al. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos. 2003 Dec;31(12):1526-30. 5- Elens et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011 Nov;57(11):1574-83. 6- Elens et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011 Oct;12 (10):1383-96. 7-Lamba et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94.





PATIENT INFORMATION

NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:

SPECIMEN TYPE: **RECEIVED DATE:**

COLLECTION DATE: 1/1/1900 1/1/1900 REPORT DATE: 2/8/2018

CYP3A5 Monograph

Clinical Utility

The cytochrome P450 3A4 and 3A5 (CYP3A4 and CYP3A5) account for 40-80% of total CYP in human liver and intestine, respectively. Most importantly, CYP3A enzymes metabolize 50% of commonly used drugs. CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity, and the contribution of CYP3A5 in the overall metabolism is smaller than the one for CYP3A4. The overall CYP3A metabolism status is expected to affect drugs that have a narrow therapeutic index.

Assay Interpretation

A limited number of variants identified within the CYP3A4 and CYP3A5 genes have been associated with significant alterations in enzyme activity and subsequent variability in therapeutic response. For CYP3A5, individuals with the less prevalent "normal metabolizer phenotype" may metabolize drugs faster than those with the more common "poor metabolizer phenotype". This may result in increased toxicity or loss of efficacy.

The CYP3A4*1B variant is the most studied, and results in an enzyme with a moderately decreased activity. It occurs in 50% of African-Americans, 3-5% of Caucasians, and <1% of Asians. The CYP3A4*2, *3, *12, and *17 are also considered decreased activity alleles. Recently, the CYP3A4 *22 allele has been characterized as a decreased function allele that can be clinically relevant (associated with a decreased clearance of certain substrates). The genotype-phenotype relationship for CYP3A4 is not well established, and individuals are predicted to have a CYP3A4 normal or intermediate metabolic capacity.

The reference range for CYP3A4 metabolic status is CYP3A4 *1/ *1, which is consistent with a normal metabolizer.

The variant results in an enzyme with no activity, and is the most common variant in the general population. This variant is found on all the CYP3A5*3 alleles. The CYP3A5 *6 and *7 are also no function alleles. The functional effects of the CYP3A5 alleles *2, *4, *5 *8, and *9 are not well established. The CYP3A5 *1 functional allele produces an active enzyme, and is found in 5% of Caucasians, 20% of Asians, and 15-50% of Africans. Individuals with two CYP3A5 no function alleles are classified as poor metabolizers while those carrying one copy of a functional CYP3A5*1 allele are considered intermediate metabolizers. A subject carrying two copies of the functional CYP3A5*1 allele is considered a normal metabolizer. CYP3A5 poor metabolizers represent 50% of Asians and 90% of Caucasians.

The reference range for CYP3A5 metabolic status is CYP3A5 *1/*1, which is consistent with a normal metabolizer. This genotype is the least prevalent in Caucasians and Asians.

Clinical Implications

CYP3A4 and CYP3A5 genotypes can help identify patients with high or low overall CYP3A activity. Although these two enzymes metabolize many drugs, the response of only a few (such as narrow therapeutic index drugs) is expected to change significantly by genetic polymorphisms. Fentanyl (Duragesic) is a narrow therapeutic drug that is mainly metabolized by CYP3A. There is limited evidence suggesting that the response to this drug is altered in individuals with abnormal CYP3A activity.

The following drugs used in pain management and various psychiatric conditions are metabolized extensively by CYP3A: fentanyl (Duragesic), oxycodone (Oxycontin), buprenorphine (Suboxone), carbamazepine (Tegretol), quetiapine (Seroquel), ziprasidone (Geodon), alprazolam (Xanax), midazolam (Versed), triazolam (Halcion), nefazodone (Serzone), trazodone (Oleptro), vilazodone (Vibryd), zaleplon (Sonata), and zolpidem (Ambien). CYP3A contributes to a small extent in the elimination of methadone (Dolophine).

Within the major therapeutic classes used in cardiovascular conditions, the following drugs are substantially metabolized by CYP3A: atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), nifedipine (Procardia), verapamil (Verelan), nicardipine (Cardene), felodipine (Plendil), nisoldipine (Sular), clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta), cilostazol (Pletal), amiodarone (Cordarone), quinidine (Qualaquin), disopyramide (Norpace), losartan (Cozaar), rivaroxaban (Xarelto), and apixaban (Eliquis).

CYP3A metabolism is highly sensitive to inhibition and induction when a patient is taking multiple drugs. In this case, occurrence of drug-drug interactions can have profound effects on the pharmacokinetics, as well as the responses and safety profiles of many CYP3A drug substrates.





 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:
 Content of the second se

SPECIMEN DETAILS

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Inhibitors

Some known **strong** CYP3A inhibitors include: boceprevir (Victrelis), clarithromycin (Biaxin), clofazimine (Lamprene), conivaptan (Vaprisol), grapefruit juice (high dose), idelalisib (Zydelig), itraconazole (Sporanox), ketoconazole (Nizoral), lopinavir, (Kaletra), nefazodone (Serzone), nelfinavir (Viracept), paritaprevir (Technivie), posaconazole (Noxafil), ribociclib (Kisqali), ritonavir (Norvir), saquinavir (Invirase), telaprevir (Incivek), telithromycin (Ketek), tipranavir (aptivus), troleandomycin (TAO) and voriconazole (Vfend).

Some known **moderate** CYP3A inhibitors include: amprenavir (agenerase), aprepitant (Emend), atazanavir (Reyataz), ciprofloxacin (Cipro), darunavir (Prezista), diltiazem (cardizem), erythromycin (Eryc), fosamprenavir (Lexiva), fluconazole (Diflucan), grapefruit juice (low dose), imatinib (Gleevec), quinupristin/dalfopristin (Synercid) and verapamil (Isoptin, Covera-HS).

Some known **weak** CYP3A inhibitors include: amiodarone (Cordarone), amlodipine (Norvasc), atorvastatin (Lipitor), bicalutamide (Casodex), cilostazol (Pletal), cimetidine (Tagamet), fluoxetine (Prozac), fluoxamine (Luvox), ranitidine (Zantac), ranolazine (Ranexa), sertraline (Zoloft) and ticagrelor (Brilinta).

Inducers

Some known **strong** CYP3A inducers include: carbamazepine (Tegretol), enzalutamide (Xtandi), fosphenytoin (Cerebyx), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin), rifapentine (Priftin) and St. John's wort.

Some known **moderate** CYP3A inducers include: artemether (Coartem), bosentan (Tracleer), dabrafenib (Tafinlar), efavirenz (Sustiva), etravirine (Intelence), modafinil (Provigil), nafcillin (Unipen), nevirapine (Viramune) and rifabutin (Mycobutin).

Some known **weak** CYP3A inducers include: aprepitant (Emend), clobazam (Onfi), dexamethasone (Decadron), Echinacea, fosamprenavir (Lexiva), lesinurad (Zurampic), methylprednisolone (Medrol), midostaurin (Rydapt), oxcarbazepine (Trileptal), pioglitazone (Actos) and rufinamide (Banzel).

References

1- Metabolic Drug Interactions. RH Levy, KE Thummel, WF Trager. Publisher: Lippincott Williams & Wilkins (March 15, 2000). 2: Zhou et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89-295 3- Isoherranen et al. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos. 2008 Jan;36(1):146-54. 4- Williams et al. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos. 2003 Dec;31(12):1526-30. 5- Elens et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011 Nov;57(11):1574-83. 6- Elens et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011 Oct;12 (10):1383-96. 7-Lamba et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94.





PATIENT INFORMATION

SPECIMEN DETAILS

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:
 Comparison

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

Factor II Monograph

Clinical Utility

Clotting Factor II, or prothrombin, is a vitamin K–dependent proenzyme that functions in the blood coagulation cascade. It is a precursor to thrombin, which converts fibrinogen into fibrin, which in turn strengthens a protective clot.

The prothrombin 20210G>A mutation in the Factor II gene results in increased levels of plasma prothrombin and a concurrent increased risk for thrombosis. Prothrombin-related thrombophilia is characterized by venous thromboembolism (VTE). This risk of thrombosis is also increased when mutations exist for other coagulation factors such as Factor V Leiden, or in presence of non-genetic risk factors such as obesity, injury, surgery, smoking, pregnancy, use of estrogen-containing contraceptives, or replacement therapy. The clinical expression of Factor II thrombophilia is variable, and many individuals may never develop thrombosis, while others may experience venous thrombotic events or pregnancy complications.

Assay Interpretation

The Factor II thrombophilia is the second most common inherited risk factor for thrombosis. The Factor II 20210G>A mutation is associated with a hypercoagulable state. In the United States, the prevalence of this mutation is 1.1% in Caucasians and Hispanics and 0.3% in African-Americans. The prevalence of heterozygosity is 2%-5% in whites and 0%-0.3% in African-Americans. The prevalence of homozygosity is approximately one in 10,000.

The reference range for Factor II 20210G>A mutation is Factor II 20210GG.

Clinical Implications

The Factor II 20210G>A mutation is associated with an elevation of plasma prothrombin levels to about 30% above normal in heterozygotes and to 70% above normal in homozygotes. Heterozygotes are at a 2- to 5-fold increased risk of an initial VTE. The risk for VTE in Factor II 20210G>A homozygotes is not well defined, but is presumed to be higher than in 20210G>A heterozygotes. Factor II 20210G>A homozygotes for Factor V Leiden and Factor II 20210G>A have an estimated 20-fold increased risk when compared to individuals without either mutation, suggesting a multiplicative elevation in risk. Certain circumstantial factors can increase the risk of thrombosis, and include: travel, central venous catheter use, pregnancy, oral contraceptive use, hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), organ transplantation, injury, age, and surgery.

References

1- Gene Review: Prothrombin-Related Thrombophilia. Kujovich (2011) Available at http://www.ncbi.nlm.nih.gov/books/NBK1148/ accessed on Mar 2013. 2-American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing. Grody et al. available at:

(http://www.acmg.net/StaticContent/StaticPages/Factor_V.pdf accessed on Mar 2013 3 - Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G > A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. 2011 Jan;13(1):67-76 4 - Segal et al. Predictive value of Factor V Leiden and Prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009 Jun 17;301(23):2472-85





PATIENT INFORMATION

NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX:

SPECIMEN TYPE: RECEIVED DATE: REPORT DATE:

COLLECTION DATE: 1/1/1900 1/1/1900 2/8/2018

Factor V Leiden Monograph

Clinical Utility

The Factor V gene encodes the coagulation Factor V. In normal conditions, Factor V is inactivated during the clotting process by the activated protein C (APC). In subjects with Factor V Leiden thrombophilia, a mutation in the gene produces a Factor V that cannot be inactivated normally by APC. As a result, the clotting process remains active longer than usual, leading to more thrombin generation. This hypercoagulable state is also increased when other mutations exist in other coagulation factors such as Factor II, or in the presence of nongenetic risk factors such as obesity, injury, surgery, smoking, pregnancy, or use of estrogen-containing contraceptive or estrogen containing replacement therapy. The clinical expression of Factor V Leiden thrombophilia is variable. Many individuals may never develop thrombosis, while others may experience venous thrombotic events or pregnancy complications. Certain circumstantial factors can increase the risk of thrombosis, and include: travel, central venous catheter use, pregnancy, oral contraceptive use, hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), organ transplantation, injury, age, and surgery. These factors are associated with the first thrombotic episode in at least 50% of individuals with a Factor V Leiden mutation.

Assay Interpretation

Factor V Leiden is the most common known inherited risk factor for thrombosis. Factor V Leiden refers to a base change (from G to A at position 1691) in the gene. As a result, Factor V is inactivated to a lesser extent and persists for longer in the circulation, leading to hypercoagulability. In the US, the frequency of the Factor V Leiden mutation varies by ethnicity, with about 5% of Caucasians, 2% of Hispanics, and 1% of African-Americans having one mutation. Only 1 in 5000 individuals have two Factor V Leiden mutations.

The reference range for Factor V Leiden mutation is Factor V 1691 GG.

Clinical Implications

About 1 in 1000 people in the U.S. experience a first venous thromboembolism (VTE) each year. VTE is caused by inherited and environmental factors, and while the Factor V Leiden mutation is present in only 15-20% of individuals with a first VTE, it is found in 50% of individuals with recurrent VTE or estrogen-related thrombosis. The risk for VTE is increased 3- to 8-fold in Factor V Leiden heterozygotes and 9- to 80-fold in homozygotes. This risk is increased further if other genetic or circumstantial factors are present. A heterozygote individual for both the Factor V Leiden and the Factor II (compound heterozygote) has an even greater risk of VTE (20-fold) than an individual with a mutation in only one factor. This illustrates the multiplicative effect of these two factors on overall thrombotic risk.

References

1- Gene Review: factor V Leiden Thrombophilia. Kujovich (2010) Available at http://www.ncbi.nlm.nih.gov/books/NBK1368/ accessed on Mar 2013. 2- American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing. Grody et al. available at:

(http://www.acmg.net/StaticContent/StaticPages/Factor_V.pdf accessed on Mar 2013. 3-Rosendaal et al. Genetics of venous thrombosis. J Thromb Haemost. 2009 Jul;7 Suppl 1:301-4. 4- Bezemer et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009 Mar 23;169(6):610-5. 5-Segal et al. Predictive value of Factor V Leiden and Prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009 Jun 17;301(23):2472-85. 6- Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. 2011 Jan;13(1):67-76





PATIENT INFORMATION

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

MTHFR Monograph

Clinical Utility

Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism and is essential for the remethylation of homocysteine. Two common mutations in the MTHFR gene: 677C>T and 1298A> result in an enzyme with decreased activity, which is linked to increased plasma homocysteine levels (i.e., hyperhomocysteinemia). Mild to moderate hyperhomocysteinemia has been identified as a risk factor for venous thromboembolism and other cardiovascular diseases such as coronary heart disease and stroke. Other conditions in which hyperhomocysteinemia is found include recurrent pregnancy loss, placental infarction, and birth defects. However, the causal role of MTHFR mutations in these conditions is not well established.

Assay Interpretation

The approximate minor allele frequencies for most populations are 30-50% for the MTHFR 1298 A variant and 18-30% for the MTHFR 677 T variant. Heterozygotes and homozygotes for the MTHFR 677C>T mutation have 60% and 30% of normal MTHFR activity, respectively. Heterozygotes and homozygotes for the MTHFR 1298A>C mutation have 80% and 60% of normal MTHFR activity, respectively.

The reference ranges for both mutations of MTHFR are 677CC and 1298AA. This is consistent with a normal MTHFR activity.

Clinical Implications

The MTHFR assay provides information about potential causes of elevated homocysteine, and approaches for addressing it.

- Homozygosity for the MTHFR 677C>T mutation (individual with MTHFR 677 TT genotype) predisposes for hyperhomocysteinemia (especially during times of folate insufficiency) and an increase in premature cardiovascular disease. Measurement of total plasma homocysteine is informative in this case.
- Compound heterozygosity (individual with MTHFR 677 CT and MTHFR 1298AC genotypes) is not associated with an increase in plasma homocysteine level. Measurement of total plasma homocysteine is informative in this case.
- Homozygosity or heterozygosity for the MTHFR 1298A>C mutation alone (individual with MTHFR 1298AC or MTHFR 1298CC genotypes) does not increase homocysteine levels. Similarly, heterozygosity for the MTHFR 677C>T mutation alone (individuals with MTHFR 677 CT genotype) does not increase homocysteine levels.
- Hyperhomocysteinemia related to MTHFR genetic mutations has been associated with neural tube defects, stillbirths, and recurrent pregnancy loss. However, because hyperhomocysteinemia is multifactorial, involving a combination of other genetic, physiologic, and environmental factors, the presence of MTHFR mutations in an individual should not be used alone to predict the risk of these conditions.
- MTHFR in depression: Low MTHFR activity may exacerbate folate deficiency in patients with depression and may increase the risk of depressive relapse or delay the response to antidepressants. Testing for homocysteine levels and serum folate levels are recommended in patients with depression. Methylfolate may substantially benefit patients with hyperhomocysteinemia and depression when used as an adjuvant to antidepressant medication.
- The response to methotrexate, a drug used in cancer and autoimmune diseases, is affected by the presence of MTHFR genetic mutations. Methotrexate intolerance is observed in individuals that are heterozygous or homozygous for the MTHFR 677C>T mutation.





NAME: Patient 35962 ACC #: 35962 DOB: 1/1/1900 SEX: SPECIMEN DETAILS

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

References

1: van der Put. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998 May;62(5):1044-51. 2: Lewis et al. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005 Nov5;331(7524):1053. 3: Kluijtmans et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996 Jan;58(1):35-41. 4: Hickey et al. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013 Feb;15(2):153-6. 5: Grody et al. ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001 Mar-Apr;3(2):139-48. 6: Gatt et al. Hyperhomocysteinemia and venous thrombosis. Semin Hematol. 2007 Apr;44(2):70-6. 7: De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer. 2009 May;45(8):1333-51. 8: Toffoli et al. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics. 2008 Sep;9(9):1195-206. 9: Clarke et al. MTHFR Studies Collaborative Group. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012 Feb;9 (2) 10: Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998 Jul;64(3):169-72. 11: Weisberg et al. The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001 Jun;156(2):409-15. 12: Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec;169(12):1267-74. 13: Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol. 2005 Jan; 19(1):59-65. 14: Reynolds EH. Methylfolate as adjunctive treatment in major depression. Am J Psychiatry. 2013 May; 170(5):560. 15: Lewis SJ, Araya R, Leary S, Smith GD, Ness A. Folic acid supplementation during pregnancy may protect against depression 21 months after pregnancy, an effect modified by MTHFR C677T genotype. Eur J Clin Nutr. 2012 Jan;66(1):97-103. 16: Delport D, Schoeman R, van der Merwe N, van der Merwe L, Fisher LR, Geiger D, Kotze MJ. Significance of dietary folate intake, homocysteine levels and MTHFR 677 C>T genotyping in South African patients diagnosed with depression: test development for clinical application. Metab Brain Dis. 2014 Jun;29(2):377-84. 17: Shelton RC, Sloan Manning J, Barrentine LW, Tipa EV. Assessing Effects of I-Methylfolate in Depression Management: Results of a Real-World Patient Experience Trial. Prim Care Companion CNS Disord. 2013;15(4). 18: Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, Yeung AS, Dording CM, Farabaugh AH, Clain AJ, Baer L, Alpert JE, Nierenberg AA, Fava M. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun;17 (2):76-86.



PATIENT INFORMATION

DOB:

SEX:

NAME: Patient 35962 ACC #: 35962 1/1/1900

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: 1/1/1900 **RECEIVED DATE:** 1/1/1900 **REPORT DATE:** 2/8/2018

OPRM1 Monograph

Clinical Utility

"Mu" opioid receptors are the most important site of action of opioid drugs. Single polymorphisms in the human mu-opioid receptor (OPRM1) have been investigated for their role in human nociception, opiate efficacy, and addiction.

Assay Interpretation

The variant mostly studied is a single substitution at position 118, from an adenine to a quanine (A118G). This variant reduces the OPRM1 receptor signaling efficiency induced by exogenous opioids. Reduced OPRM1 mRNA expression levels were observed in carriers of the G variant. The variant allele (G) is present in 7-15% of Caucasians, 1.5% of African-Americans, and up to 48.5% of Asians. The major interest of this particular SNP is due to its pharmacological and physiological consequences; however the exact mechanism by which the altered receptor influences opioid analgesia is still unresolved. The presence of the G allele seems to reduce the effect of exogenous agonists but increase the effects of exogenous antagonists.

The reference range for the A118G SNP is A118G AA, and is associated with a normal OPRM1 receptor signaling efficiency.

Clinical Implications

The presence of the G allele (A118G) seems to be associated with pain sensitivity as well as opioid dosage requirements. But only weak evidence of these associations is available to date. It is suggested that patients carrying the G allele report higher intensity pain. In terms of drug response, patients with the G allele have a favorable response to the anti-addictive drug naltrexone. Several studies conducted in postsurgical settings or in cancer analgesia showed that G allele carriers require slightly higher doses of morphine or fentanyl. This association still needs to be confirmed in larger studies and does not hold in other situations such as labor pain.

References

1: Wu et al. Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diagn Ther. 2009;13(5):331-7. 2: Menon et al. The human µ-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients. J Headache Pain. 2012Oct;13(7):513-9. 3: Olsen et al. Pain intensity the first year after lumbar disc herniation is associated with theA118G polymorphism in the opioid receptor mu 1 gene: evidence of a sex and genotype interaction. J Neurosci. 2012 Jul 18;32(29):9831-4. 4: Reyes-Gibby et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007 Jul;130(1-2):25-30. 5: Lötsch et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009 Jun;19(6):429-36. 6: Walter C, Lötsch J. Metaanalysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain. 2009 Dec;146(3):270-5. 7: Zhang et al. Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia. 2010Feb;65(2):130-5. 8: Zhang et al. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol. 2011 Jan;77 (1):33-9. 9: Oertel et al. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics. 2006 Sep;16(9):625-36. 10: Zwisler et al. Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. J Clin Pharmacol. 2011 Mar 24. 11: Klepstad et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011 May;152(5):1139-45. 12: Kadiev E, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol. 2008 Jan;4(1):77-91. 13: Vuilleumier et al. Pharmacogenomic considerations in opioid analgesia. Pharmagenomics Pers Med. 2012;5:73-87. 14: Walter et al. µ-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. Pharmacogenomics. 2013 Nov;14(15):1915-25. 15: Thorsell A. The µ-opioid receptor and treatment response to naltrexone. Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. 16: Setiawan et al. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. Pharmacogenomics. 2012 Jul;13(10):1161-72. 17: Kranzler et al. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol. 2013 Jan;18 (1):193-201. 18: Chamorro et al. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012 May;17(3):505-12.





PATIENT INFORMATION

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

SLCO1B1 Monograph

Clinical Utility

The SLCO1B1 gene encodes a liver-specific transporter involved in the removal of endogenous compounds (bile acids, bilirubin) and drugs such as statins from the blood to the liver. Some variants of the SLCO1B1 gene result in a low-functioning protein, which impairs statin clearance, and may lead to an increased risk of muscle pain, tenderness, or weakness, called myopathy. Certain medications can potently inhibit SLCO1B1, causing clinically significant drug interactions.

Assay Interpretation

The functional SLCO1B1 activity (phenotype) is estimated from the genotype at 521T>C. Non-carriers of the 521T>C variant are predicted to have a SLCO1B1 normal function, those with one copy of the 521T>C variant have a SLCO1B1 decreased function, and those with two copies of the variant have poor SLCO1B1 function.

There are several variants of the SLCO1B1 that define over 15 alleles. One relatively common variant 521T>C (rs4149056) results in SLCO1B1 decreased function, which affects the transport of drug substrates such as statins. This variant is present alone on the *5 allele and in presence with another variant (388A>G; rs2306283) on the *15 allele. Both alleles are low-activity alleles (reduced hepatic uptake), and have a combined frequency of 15-20% in Caucasians, 10-15% in Asians, and 2% in sub-Saharan Africans and African-Americans.

The reference range for the 521T>C mutation of SLCO1B1 is 521 TT. This is consistent with normal SLCO1B1 function.

Clinical Implications

All statins are substrates of SLCO1B1, but the effects of SLCO1B1 genetic polymorphism differ between individual statins. The effect is the largest on simvastatin, and individuals with the 521T>C variant have increased levels of the active simvastatin form. The variant is strongly associated with simvastatin-induced myopathy (with or without CK elevation), especially with high-dose simvastatin therapy. More than 60% of the myopathy cases could be attributed to its presence. The clinical spectrum of statin-induced myopathy ranges from a mild and common myalgia to a life-threatening and rare rhabdomyolysis. Other known risk factors for statin-induced myopathy include a high-statin dose, interacting drugs that raise statin levels, age, hypothyroidism, and certain inherited muscle disorders.

At therapeutic doses, the apparent sensitivity levels of the five statins to the presence of the 521T>C variant are simvastatin>pitavastatin>atorvastatin>pravastatin>rosuvastatin. Carriers of the 521 T>C variant should avoid high-dose simvastatin therapy. These patients can take other statins, such as atorvastatin, pitavastatin, rosuvastatin, or pravastatin, but at reduced doses. Fluvastatin is not affected by the 521 T>C variant and could therefore be considered a suitable alternative.

Other drugs that are substrates of SLCO1B1 transporter include enalapril, olmesartan, valsartan, atrasentan, repaglinide, nateglinide, methotrexate, and bosentan. However, there is insufficient evidence documenting the impact of the 521 T>C variant on the systemic exposure and safety profile of these drugs.

Inhibitors

Inhibitors of SLCO1B1 transporter may alter its activity and result in increased levels of drug substrates. These include boceprevir (Victrelis), clarithromycin (Biaxin), cyclosporine (Gengraf, Neoral, Restasis, Sandimmune), eltrombopag (Promacta), gemfibrozil (Lopid), paritaprevir (Technivie), protease inhibitors, simeprevir (Olysio), telaprevir (Incivek) and teriflunomide (Aubagio).

References

1: FDA Zocor Prescribing Label: http://www.accessdata.fda.gov 2: 1: Wilke et al. Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and sinvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112-7. 2: Feng et al. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics.2012 Apr;13 (5):579-94. 3: Elsby et al. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther. 2012 Nov;92(5):584-98. 4: SEARCH Collaborative Group, Link E. SLCO1B1 variants and statin-induced myopathy--a genome wide study. N Engl J Med. 2008 Aug 21;359(8):789-99. 5: Nies et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 2013 Jan 11;5(1):1. 6 : Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010 Jan;87(1):130-3. 7 : Niemi et al. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. 8: Neuvonen et al. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.





PATIENT INFORMATION

 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

 SEX:

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

VKORC1 Monograph

Clinical Utility

The Vitamin K epoxide reductase complex, subunit 1 (VKORC1) is the target of anticoagulants such as warfarin, acenocoumarol and phenprocoumon. VKORC1 catalyzes the conversion of oxidized Vitamin K to reduced Vitamin K. By inhibiting this conversion, warfarin leads to decreased availability of the reduced Vitamin K that serves as a cofactor for gamma-glutamyl carboxylase and blocks the formation of functionally-active clotting factors, resulting in reduced coagulation. Polymorphisms within the VKORC1 gene result in variable expression levels of the VKORC1 enzyme and altered response towards coumarin anticoagulants. VKORC1 genetic testing defines three clinical phenotypes: high, moderate, and low sensitivity to warfarin. VKORC1 genetic testing is usually used in conjunction with CYP2C9 and CYP4F2 genetic testing to optimize warfarin dosing and minimize the risks of bleeding or thrombotic complications.

Assay Interpretation

Several relevant variants in the VKORC1 gene have been identified and correlate well with warfarin dose requirements. In Europeans, the genotype for a single variant (-1694G>A; rs9923231) accounts for 25% of variability in warfarin dose requirements, with the minor A allele associated with lower doses. This association is also observed in East Asians, where the minor allele occurs more frequently than in Europeans (88% vs 41%). In Africans, the minor allele frequency for VKORC1 -1639G>A is 10% which is considerably lower than in Europeans. Several studies in Africans and African-Americans identified common variants that are associated with higher warfarin dose requirements in patients of African descent.

The reference range for VKORC1 -1639G>A is G/G and is associated with a normal VKORC1 enzyme expression phenotype.

Clinical Implications

The common VKORC1 -1639G>A variant is associated with low-dose warfarin requirements. When CYP2C9 and VKORC1 genotypes are combined with other patient-specific parameters such as demographic (age, weight, height), clinical (disease, co-medications), and environmental factors (smoking), they account for 50% of warfarin dose variation between individuals. Several validated warfarin pharmacogenetic dosing algorithms have been developed and are available to calculate initial and maintenance warfarin doses in both adults and children. Moreover, the FDA prescribing label for warfarin includes genotype-specific dose ranges based on CYP2C9 and VKORC1 genotypes.

References

1: Food and Drug Administration: Coumadin® Label accessed on Jan 2013. 2: Gage et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep;84(3):326-31 3: Schelleman et al. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol. 2010 Sep;70(3):393-9 4: Johnson et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011 Oct;90(4):625-9. 5: Klein et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. International Warfarin Pharmacogenetics Consortium. N Engl J Med. 2009 Feb 19;360 (8):753-64 6: Rieder et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005 Jun 2;352(22):2285-93. 7: Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017 Sep;102(3):397-404.





 NAME:
 Patient 35962

 ACC #:
 35962

 DOB:
 1/1/1900

SEX:

SPECIMEN DETAILS

 SPECIMEN TYPE:

 COLLECTION DATE:
 1/1/1900

 RECEIVED DATE:
 1/1/1900

 REPORT DATE:
 2/8/2018

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Patient Information Card

This is a summary genetic report for your patient to share with other healthcare providers. The card can be cut out along the dashed line and carried with the patient.

Manchester University		REPORT DETAILS				
		Patient: Patient 35962 DOB: 1/1/1900 1/1/1900 ACC #: 35962	VKORC1	-1639G>A A/A	High Warfarin Sensitivity	
			MTHFR	1298A>C AA 677C>T CC	No Increased Risk of Hyperhomocysteinemia	
	Pharmacoge	netic Test Summary	MTHFR	677C>T CC	Normal MTHFR Activity	
CYP2C19	*1/*17	Rapid Metabolizer	Factor II		No Increased Risk of Thrombosis	
CYP2C9	*1/*1	Normal Metabolizer	Factor V	20210G>A GG 1691G>A GG		
CYP2D6	*1/*1	Normal Metabolizer	Leiden	1691G>A GG		
CYP3A4	*1/*1	Normal Metabolizer	For a comple	For a complete report contact Manchester University Master of Scie		
CYP3A5 *3/*3 Poor Metabolizer			in Pharmacogenomics Program www.manchester.edu/pgx			